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ABSTRACT 
 
IRENE M. BASKERVILLE-ABRAHAM: Molecular Dosimetry of 1,2 Guanine-Guanine 
Intrastrand Cross Links of Cisplatin by Ultra Performance Liquid Chromatography 
Tandem Mass Spectrometry 
(Under the direction of James A. Swenberg and Stephen G. Chaney) 
 
 Cisplatin has been extensively studied as an antitumor agent since the 
late 1960s.  However the mode of action for the efficacy and adverse effects 
of cisplatin are poorly understood.  It was previously believed that the 
cisplatin1,2 intrastrand guanine-guanine [CP-d(GpG)] cross link was likely 
responsible for much of the cytotoxic actions of the compound.  But current 
techniques prevented accurate and specific adduct quantification using 
pharmacologically relevant concentrations of cisplatin. Therefore, the 
development of a highly sensitive and specific method to measure the CP-
d(GpG) cross link was begun.  Using this technique, this dissertation aimed to 
study the role of CP-d(GpG) in acquired resistance and different genetic 
profiles.  
The developed mass spectrometry method is able to measure 3.7 
adducts per 108 nucleotides using 25 µg of DNA per injection. Preliminary 
results indicated that the method was sensitive enough to quantify adducts in 
ovarian carcinoma cells using as little as 12.5 µM cisplatin.  It was also able to 
quantify adducts the kidney, liver and colon tissues of mice that had been 
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given 7 mg/kg cisplatin by i.p. injection.  Our hypothesis was that the density 
of CP-d(GpG) cross links would serve as a useful biomarker for efficacy 
and/or toxicity of cisplatin.  Research was conducted to understand CP-
d(GpG) formation in ovarian carcinoma cell lines as well as in 8 inbred strains 
of mice. 
Results indicate that the dose response relationship for adduct 
formation in our isogenic cisplatin sensitive and resistant cell lines remains 
linear, when using lower more pharmacologically relevant doses of cisplatin. 
In mice, adducts were most concentrated in the kidney.  Of the 8 inbred 
strains tested the C57BL/6J mice were the most sensitive and FVB/NJ least 
sensitive to cisplatin treatment.   Toxicity, as determined by histopathology, 
did not correlate with CP-d(GpG) molecular dosimetry.  However, this lack of 
correlation may be due to the design of the mouse study, as such many 
suggestions for future animal studies are given.  Based on reported 
concentrations of platinum DNA adducts clinical samples, the sensitivity and 
specificity of our method could provide additional insight as to the role of CP-
d(GpG) adduct formation in cancer patients being treated with cisplatin.  
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CHAPTER 1 
INTRODUCTION 
 
1.1  Significance 
 Cis-diamminedichloroplatinum(II) (cisplatin) is a widely used 
chemotherapeutic agents (Figure 1.1).  Cisplatin (CP) is an inorganic compound in 
which the platinum atom is bound to two amine groups and has two chloride leaving 
groups.  This compound undergoes a non-enzymatic conversion in physiologic 
solutions to active derivatives via displacement of leaving groups.  This leads to the 
formation of mono, inter- and intra-strand DNA adducts.  The formation of these CP-
DNA adducts is believed to be necessary for the anticancer activity of platinum 
drugs.  Of DNA adducts formed, the intrastrand cross links are the most prevalent, at 
over 95% (1,2).  These intrastrand cross links are formed at the N7 position of 
adjacent AGs or GGs (Figure 1.2).  The repair of these DNA adducts occurs 
primarily by the nucleotide excision repair (NER) pathway (3).  Replication and 
transcription are inhibited upon the binding of these agents to DNA.  Each 
compound also forms adducts with glutathione, proteins and other nucleophiles (4-
6).  The DNA adducts are recognized by both high mobility group (HMG)-domain and 
damage recognition proteins.  The HMG-domain proteins specifically recognize 1, 2 
intrastrand DNA cross links of cisplatin adducts (7,8) and inhibit their repair, leading 
to increased drug efficacy (9).  
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The mode of action for the efficacy and adverse effects are poorly 
understood.  Current research postulates that the target of these compounds is DNA 
and the resulting cytotoxicity of these agents causes cell death, via apoptosis or 
necrosis.  If cell death does not occur, unrepaired adducts may lead to mutations, 
which can initiate secondary cancers.  Many studies have been performed regarding 
platinum resistance and its relationship with genetic polymorphisms, alterations in 
gene expression and protein levels (10-13).  Another aspect that needs to be 
considered is the idea of repair of adducts versus the tolerance of adducts.  Most 
studies of resistance mechanisms do not make comparisons between cells lines on 
a per-adduct basis.  Therefore, one cannot discriminate between differences due to 
decreased uptake/increase repair and a real difference in gene expression in 
response to an equal number of adducts.  In the case of tolerance, a reduction in 
cytotoxicity or increased dose at which a cytotoxic endpoint becomes apparent is 
observed in comparison to equivalent measurements in the absence of the tolerance 
mechanism of interest.  However, there is not a sensitive and specific method 
allowing investigators to discriminate between alterations caused by inter-individual 
differences in gene/protein expression and adduct burden.  The development of 
biomarkers to determine tissue-specific molecular dosimetry during various 
chemotherapeutic treatments will lead to a more complete understanding of both 
therapeutic and adverse effects.  This will support the refinement of therapeutic 
regimens and appropriate individualized treatment protocols.  Our research provides 
a sensitive and specific way to quantify these adducts that will enhance 
pharmacogenomic data that are indexed to the adduct burden achieved in either 
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tumor tissue or surrogate markers such as circulating lymphocytes.  Ultimately this 
will lead to more efficacious, less toxic individualized targeted therapies, and provide 
improved indicators of prognosis. 
 
1.2  DNA, the Primary Cellular Target 
 When entering the body by i.v., the high concentration of chloride ions (100 
mM) suppresses hydrolysis and maintains cisplatin in a nonreactive state.  The 
limiting factor for accumulating platinum in cells is its concentration.  It was once 
believed that the uptake of cisplatin was not saturable and was only by passive 
diffusion.  While passive diffusion still plays a role in cisplatin uptake, recent 
research suggest that carrier mediated transport may occur in some cell types.  
Once inside the cell, the diminished chloride ion concentration (~20 mM) allows 
hydrolysis to occur, resulting in an active aquated form, which reacts readily with 
cellular targets. 
 Proteins, RNA, and DNA are among the cellular components that react with 
cisplatin.  Studies of the effects of platinum compounds upon these components 
were performed to gain more insight as to the primary target of cisplatin.  One study 
used HeLa cells in conjunction with a colony forming assay to examine the amount 
of platinum bound to macromolecules (14).  A calculation was performed utilizing a 
set amount of platinum bound for DNA, RNA and proteins versus the number of 
platinum atoms bound in the surviving cells.  The study showed that 22 platinum 
atoms were bound per DNA molecule compared to one Pt per 8 mRNA, one per 30 
rRNA, one per 1500 tRNA, and one per 1500 protein molecules.  Another study 
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using HeLa cells was performed with 195Pt-radiolabeled cisplatin showing that as 
little as 1 out of 3x105 protein molecules and 1 out of 1000 RNA molecules 
contained a platinum atom (15).  However, in DNA they observed that nine platinum 
atoms were bound per molecule.  This experimental evidence supports the generally 
accepted belief that DNA is the primary target of cisplatin in cells.   
 
1.3  DNA Adduct Formation 
 With DNA established as the primary target of cisplatin in cells, investigators 
next investigated the binding interaction to characterize the adducts formed.  
Because platinum compounds that are ineffective as therapeutic agents only bind 
monofunctionally, protein-DNA, intra-, and inter-strand cross links were thought to be 
important for biological activity because of their bifunctional conformation.  To gain 
more insight, Fitchtinger-Schepman performed an enzymatic digestion of salmon 
sperm DNA followed by chromatographic separation of the products and NMR 
analysis to identify the major DNA adducts of cisplatin (16).  The major products 
were 1,2-intrastrand cross links involving adjacent bases, with cis-
[Pt(NH3)2{d(GpG)}] or CP-d(GpG) comprising 47-50% of the adducts formed and cis-
[Pt(NH3)2{d(ApG)}] or CP-d(ApG) comprising another 23-28%.  Additionally, 8-10% 
of the digested products contained 1,3-intrastrand cross links involving non-adjacent 
guanines (CP-GNG) and interstrand adducts, and another 2-3% of the products 
were due to the monofunctional binding to guanine.  In each case, platinum was 
bound to the N7 atom of purine bases.  Eastman performed a similar study using 
DNA modified by [3H]-[Pt(en)Cl2], which was believed to have a similar adduct profile 
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to cisplatin and found 65% CP-d(GpG), 25% CP-d(ApG), and 6% CP-GNG adducts 
(17).  
 These in vitro experiments provided evidence that the 1,2-intrastrand adducts 
were the major adducts formed by cisplatin.  The DNA adduct formation was then 
examined in cells using immunochemical assays. Some studies have attempted to 
correlate the level of intrastrand adducts to treatment response.  In one such study, 
lymphocytes taken from cancer patients treated with cisplatin displayed a similar 
adduct profile to the in vitro studies (18).   
 To aid in the determination of clinical relevance of cisplatin DNA adducts, one 
should also consider its clinically ineffective isomer, transplatin (TP), which forms 
different types of DNA cross links.  Each compound forms bifunctional DNA adducts 
that bind to the N7 positions of guanine and adenine.  However, due to its 
stereochemistry, transplatin is unable to form 1,2-intrastrand d(GpG) or d(ApG) 
adducts.  Enzymatic digestion studies of DNA treated with transplatin show the 
formation of 50% dG-TP-dC, 40% dG-TP-dG, and 10% dG-TP-dA (19).  Thus, 
treatment with transplatin leads to the formation of 1,3-intrastrand and interstrand 
cross links.  Cisplatin binding to DNA is kinetically controlled.  As mentioned 
previously, a chloride ligand hydrolyzes when cisplatin enters cells, forming cis-
[Pt(NH3)2Cl(H20)]+ or monoaquated cisplatin.  This hydrolysis reaction is the rate 
limiting step for DNA binding, with a half life of ~2h.  Monoaquated cisplatin then 
binds to an N7 atom of a guanine base, which displaces the water molecule (t1/2~0.1 
h), forming a monofunctional adduct.  Closure of the monofunctional adduct to form 
a bifunctional adduct involves hydrolysis of the second chloride ligand, with a half life 
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of ~2h.  If we once again compare cisplatin to transplatin, we find that the first 
hydrolysis step and binding to DNA to form monofunctional adducts occurs at a 
similar rate.  Therefore, a different rate of closure to form the bifunctional adduct by 
hydrolysis of the 2nd chloride ligand taken together with its inability to form 1,2 
intrastrand cross links, may explain the difference in adduct formation and therefore 
biological activity between these isomers.  Studies on this subject are at odds, some 
suggest rates to be similar (t1/2~3 h) (20), while others argue that transplatin forms 
bifunctional adduct much more slowly (t1/2>24 h) (21).  Differences in study design, 
such as the length of DNA duplex and the concentration of platinum adducts, can 
affect the rate of closure.  Overall, this implies that the slow formation of interstrand 
and 1,3 intrastrand cross links combined with the inability of transplatin to form 1,2-
intrastrand cross links, play a large role in its difference in clinical efficacy. 
 The processes just described suggest that the 1,2 intrastrand adducts of 
cisplatin may be important to its anticancer activity.  These major adducts are 
formed both in vitro and in vivo.  Furthermore, the clinically ineffective transplatin 
cannot form these cross links.  Also previously mentioned was the positive 
correlation of the level of these cisplatin adducts to treatment response.  Numerous 
studies have shown CP-d(GpG) as the most prevalent cisplatin DNA adduct.  
Therefore, our studies have focused on developing a method to quantify the 1,2 
guanine-guanine DNA adduct of cisplatin to aid in the determination of the role it 
may play in the cisplatin anticancer mechanism. 
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1.4  Rationale for Development of New Mass Spectrometric Method 
Our research is based upon the premise that DNA is the intracellular target of 
cisplatin chemotherapy.  Therefore the formation of 1,2- intrastrand DNA adducts is 
an important component of the mode of action.  The development of a specific and 
sensitive mass spectrometric method will provide crucial molecular dosimetry data 
and allow better understanding of the mode of action for these compounds.  Studies 
have attempted to evaluate the role of Pt-DNA adducts in vivo; however, the 
sensitivity and specificity of the methods limited the quality of data obtained. 
Common methods used to measure Pt-DNA adducts include antibody probes, 32P 
post labeling, atomic absorption spectroscopy, inductively coupled plasma mass 
spectrometry, and electrospray ionization mass spectroscopy.   
 
1.4.1  Antibody Probe Based Methods 
There are several assays utilizing antibody probes to determine the level of 
platinum adducts.  However these assays are often cross reactive and have a non-
linear dose response, making accurate quantitation of specific adducts difficult.  The 
first immunoassay for the detection of cisplatin adducts was a radioimmunoassay 
(22).  However experiments with carcinogen-DNA antisera exhibited a 10- to 100-
fold increase in sensitivity when utilized in ELISA, therefore to gain sensitivity, a new 
study was performed using an antibody elicited against cisplatin modified DNA in an 
ELISA inhibition assay (23-25).  In this study, a polyclonal antibody was used to 
detect total cisplatin adducts formed in vivo and cited a lower limit of detection 
(LLOD) of 0.2-0.3 fmol total platinum adducts/µg DNA.  However, once the authors 
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compared their data to similar studies performed with lower concentrations of 
cisplatin and atomic absorption spectroscopy (AAS) to measure total Pt, they 
postulated that their antibody may not detect all of the platinum associated with DNA 
in vivo.  This was due to the ELISA assay showing lower adduct levels (0.27 and 10 
fmol/µg DNA) as compared to AAS (10-45 fmol of Pt per µg DNA).  Later, a 
comparison by Fitchtinger-Schepman of two different ELISA assays to determine 
cisplatin-DNA adducts in the blood cells of cisplatin-treated cancer patients would 
show more shortcomings of the Poirier designed antibody (26).  While Poirier et al 
had determined the adducts in native DNA with an antiserum raised against highly 
modified cisplatin DNA, Fichtinger-Schepman et al. assayed the various adducts 
after chromatography of enzymatically digested DNA samples using antibodies 
raised against synthetic haptens mimicking the Pt-containing digestion products 
(25,26).  When identical human samples were analyzed by both methods, 14-300-
fold higher adduct levels were found with the Fichtinger-Schepman method and AAS 
further confirmed the results of the Fichtinger-Schepman assay (26).  As mentioned 
previously, AAS showed a difference of up to a factor of 1000 in the original Poirier 
study, further emphasizing the importance of carefully selecting an appropriate 
antibody.  Furthermore, when Fitchtinger-Schepman used the Poirier method to 
analyze samples modified to a level similar to that of cisplatin-treated patients, no 
adducts could be detected.  Next, a monoclonal antibody to detect DNA modification 
by cisplatin and carboplatin in vivo and in vitro was published in 1991 (27).  This 
assay cited quantitation of cisplatin-induced DNA adducts at 3 nmol Pt/g DNA or 1 pt 
adduct per 106 bases when using ICR4 (the monoclonal antibody) in a competitive 
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ELISA assay.  This method could detect below this level, but cross-reactivity of 
unmodified DNA sequences complicated quantitation.  Terheggen et al attempted to 
design antibodies (NKI-A68, A10, A39) which detect specific cis-DDP DNA adducts 
(CP-d(ApG), CP-d(GpG) and CP-dGMP), as well as one against total cisplatin 
modified DNA (NKI-A59) to aid the studies of binding of cisplatin to cellular DNA 
(28).  The antibodies for individual adducts were deemed suitable for platinum-DNA 
adduct analysis of digested DNA in ELISA assays.  However, the cross reactivity of 
these antibodies prevent specific quantitation of any one of these adducts.  Several 
other investigator developed monoclonal and polyclonal antibodies in an attempt to 
gain more sensitivity and specificity (29-31).  As technology changed, investigators 
moved from using their antibodies in comparative ELISA to techniques involving 
microscopy (32).  One group was able to design an antibody with high sensitivity to 
cisplatin-DNA adduct involving adjacent guanine residues, however immuno-
recognition was influenced by the surrounding DNA sequence (33).  Most recently, 
Liedert et al. used monoclonal antibodies (Mab R-C18 and R-B3) to recognize Pt-
d(GpG) and Pt-d(ApG) using an immuno-cytological assay.  Their assay quantifies 
drug induced lesion in individual cell nuclei (34).  While their method may be useful 
for histological studies, cross reactivity of this antibody still prevents specific 
quantification of individual cisplatin DNA adducts. 
 
1.4.2  32P Postlabeling Based Methods 
In 1990 Mustonen and Hemmiki published their application of a 32P-postlabeling 
technique to detect DNA adducts formed by cisplatin and other methylating agents 
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(35).  This method did not differentiate between the individual cisplatin adducts and 
was used in vitro. Four years later, Hemmiki and Forsti modified this method to 
enable the detection of cisplatin adducts in platinated calf thymus DNA (36). Next in 
1995, Blommaert and Saris developed a sensitive version of 32P-postlabeling that 
allowed the detection of the in vitro and in vivo bifunctional intrastrand crosslinks, Pt-
d(ApG) and Pt-d(GpG) of cisplatin and carboplatin (37).  This method added strong 
cation exchange chromatography after the enzymatic digestion of platinated DNA to 
separate the DNA adducts from unplatinated products.  Because the platinated 
dinucleotides were poor substrates for polynucleotide kinase, the samples were 
deplatinated with cyanide.  After excess cyanide was removed using Sep-pak C18 
cartridges, the resulting dinucleotide monophosphates, d(GpG) and d(ApG), were 
postlabeled.  The detection limit of this assay was 1 adduct per 107 nucleotides 
using 10 µg of DNA.  This procedure was found to have good correlation with other 
methods, such as AAS and ELISA, for platinum DNA adduct detection in vitro and in 
vivo with both cis- or carboplatin (37).  This group then studied the formation of 
platinum DNA adduct in vitro in calf thymus DNA and in cell culture using cisplatin, 
lobaplatin, and oxaliplatin through comparison of AAS and their new sensitive 32P-
postlabeling method (38).  They found that cisplatin formed a substantially higher 
rate of adducts in comparison to lobaplatin and oxaliplatin.  However, no conclusions 
could be reached as to the cytotoxicicty of the Pt-d(GpG) and Pt-d(ApG) adducts 
because their ratios in ovarian carcinoma (A2780) cells were not significantly 
different for any of the platinum compounds.  Welters et al. published an 
improvement to the Blommaert and Saris method in 1997 (39).  Their improvements 
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included the addition of TpT as an internal standard, which had equally efficient 32P-
labeling as GpG and ApG.  This internal standard was added immediately after 
isolation of the Pt-adducts from digested DNA samples.  Another improvement was 
to adjust the pH of the DNA digests to ~3 prior to strong cation exchange 
chromatography to assist in the isolation of the Pt-adduct on the basis of a positive 
charge.  They also decreased the amount of cyanide used for deplatination therefore 
removing the interference with the labeling step.  This method was used to 
determine adduct levels in cisplatin-treated DNA, DNA from cisplatin-treated cultured 
cells, tumor xenografts from cisplatin-treated mice, and from white blood cells and 
tumor tissues from cisplatin-treated patients.  Samples with high levels of adducts 
showed significant correlation with atomic absorption spectroscopy while those with 
low levels showed correlation with specific antibodies used in an ELISA assay (39).  
Further improvements by this group increased the sensitivity to 87 and 53 amol per 
µg DNA (40). 
 In the late 1990s, several groups started to use this method to determine 
platinum DNA adduct formation in clinical studies.  Because the response to cisplatin 
therapy was assumed to be related to the formation of platinum DNA adducts, 
Welters et al. decided to measure platinum adducts prior to therapy using 32P-
postlabeling after ex vivo cisplatin treatment of head and neck squamous cell 
carcinoma (HNSCC) xenografts and of tumor biopsies from patients with HNSCC 
and testicular cancer (41).  They observed that higher adduct levels during the one 
hour exposure to 10 to 80 µM cisplatin were associated with better responses.  
During the following five hour drug free incubation only adducts in the testicular 
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cancer samples persisted, which is of interest since platinum therapy is curative for 
testicular cancer.  These results show analysis of DNA adducts following ex vivo 
drug treatment to be one possibility for a predictive assay for patients who may 
undergo platinum based therapy.  Another group used 32P-postlabeling to test the 
predictive value of cisplatin-DNA adduct levels in HNSCC patients treated with 
cisplatin and concurrent radiation (42).  Adducts were quantified in normal and tumor 
tissues.  Adduct levels were correlated with treatment outcome.  Patients with higher 
GG adduct levels (>median) in primary tumor had significantly better disease free 
survival (DFS) than patients with lower (< or = median) adduct levels (p = 0.02).  For 
overall survival (OS), a non-significant trend was observed; again in favor of patients 
with higher adduct levels (p = 0.06).  Therefore in this study, cisplatin-DNA adduct 
formation in primary tumor appears to be predictive for DFS in HNSCC.  Recently, 
this group used 32P-postlabeling to show the lack of a correlation of formation of 
cisplatin-DNA adducts between normal (WBC and buccal cells) and tumor (biopsy) 
tissue (43).  This suggests that cisplatin-DNA adducts can be used as a predictive 
test in anticancer platinum therapy, if the correct tissue is used.  It would be of 
interest to see if normal tissue (other than WBC or buccal cells) could be used 
effectively for a predictive test.  For instance, animal studies could be performed to 
learn whether tumor and normal tissue from the same organ type form and retain 
cisplatin-DNA adducts to the same extent or not. 
In summary, the 32P-postlabeling shows a high level of sensitivity for CP-
d(ApG) and CP-d(GpG) adducts, which has made it useful for determining platinum 
adduct levels in clinical studies.  However, it is a time consuming method and 
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requires the use of radioactivity.  Additionally, there are several possible sources of 
error in this method.  First, the internal standard used in this method is added late in 
sample preparation and is not platinated or structurally identical to measured adduct. 
Furthermore, adducts must be deplatinated before labeling, causing possible loss of 
adducts (37,40,44).  Finally, there is no structural confirmation of the platinated 
adduct, which may lead to over or under estimation of adducts.  This method has 
shown good correlation to atomic absorption spectroscopy and antibody probe 
based assays, which are both less sensitive than this method. 
 
1.4.3  Methods Measuring Total Platinum 
1.4.3.a  Atomic Absorption Spectroscopy  
Atomic absorption spectroscopy (AAS) has long been used to determine the 
amount of total platinum in a given sample.  A recent PubMed search of cisplatin 
and atomic absorption spectroscopy resulted in over 300 papers.  In 1976, Litterst et 
al. used AAS to study distribution of a single i.v. dose of cisplatin in female beagle 
dogs (45).  Platinum concentration was measured in the plasma, bile, urine, as well 
as sixteen tissues.  This was one of the first in vivo studies of pharmacokinetics of 
cisplatin.  The data from this study suggested that cisplatin bound tightly to plasma 
albumin, was rapidly excreted through the urine, and stayed bound longer in the 
kidney, liver, ovary, and uterus.  
AAS requires a large amount of DNA and/or high concentration of platinum 
for determination of total platinum and therefore is not sensitive enough for use with 
most clinical samples (46-50).  As mentioned previously, Fitchtinger-Schepman et al. 
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found the following distribution of cisplatin adducts: CP-d(GpG) 47-50% , CP-d(ApG) 
23-28%, CP-GNG 8-10%, and 2-3% were due to monofuctional binding to guanine 
(16).  Calculations using these ratios are used with AAS to obtain estimates of 
individual adduct formation.  Furthermore, the high concentration of platinum 
sometimes required researchers to assume a linear extrapolation in order to 
correlate molecular dose and effect in experiments using more biologically relevant 
concentrations of cisplatin.   
Another PubMed search of cisplatin, atomic absorption spectroscopy and 
adducts led to papers showing the AAS method in comparison to new methods, 
such as ELISA, 32P-postlabeling, HPLC-ICP-MS, in which each can measure 
individual platinum adducts.  One example is a paper by Welters et al, in which they 
were studying the pharmacodynamics of cisplatin in head and neck cancer using 
AAS and 32P-postlabeling (51).  Sensitivity to cisplatin was correlated with total 
platinum and CP-DNA adduct levels were determined in vivo in xenografted tumor 
tissues in mice and in vitro in cultured tumor cells of HNSCC.  They found significant 
correlations between total platinum levels, measured by AAS, and tumor response to 
cisplatin therapy in vivo and in vitro.  However, sensitivity of the in vivo tumors did 
not coincide with the corresponding cell lines.  Interestingly, a significant correlation 
was found between the CP-d(ApG) levels and sensitivity to cisplatin both in vitro and 
in vivo, using 32P-postlabeling.  These correlations suggest that the CP-d(ApG) 
adduct is responsible for cytotoxicity in this model system.  It would be interesting to 
revisit this study with our method to see if the observed correlation remains or if it 
was possibly due to an overestimation of CP-d(ApG) adducts by 32P-postlabeling. 
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1.4.3.b Inductively Coupled Plasma Mass Spectrometry  
Inductively coupled plasma mass spectrometry (ICP-MS) measures total 
platinum with higher sensitivity than AAS, allowing its application to clinical samples.  
One group has reported an ability to approach the sensitivity of the 32P-postlabeling 
method using ICP-MS (52).  However, they further reported that this level of 
sensitivity could not be obtained with the addition of HPLC speciation, which is 
necessary for quantification of the individual adducts.  Previously, a capillary HPLC-
ICP-MS method was reported to measure CP-d(GpG) adducts specifically; this 
method reported a limit of quantitation (LOQ) of ~ 1 adduct per 106 nucleotides, 
however it lacked adequate sensitivity to measure samples treated with <500 µM 
cisplatin (53).  Mutagenesis assays using <10 µM cisplatin have been reported in the 
literature (54).  Therefore, greater sensitivity is needed to ensure direct comparisons 
of the formation and/or persistence of individual cisplatin adducts and the induction 
of mutations.  During the development of the UPLC-HESI-MS-MS method we found 
that for ICP-MS to be effectively used for trace analysis (< 1 ppb) or measurement of 
cisplatin adducts (<20 picomoles or <6 per 106 nucleosides) a clean room and ultra 
sensitive mode must be utilized.  While both AAS and ICP-MS technologies are 
useful in screening for DNA adducts, measurements of the distribution of mono CP 
adducts, inter- or intra- strand CP-cross links would allow the correlation of specific 
CP adducts with biological effects.  
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1.4.4  Liquid Chromatography Electrospray Ionization Mass Spectrometry  
Liquid chromatography electrospray ionization mass spectrometry (LC-ESI-
MS) measurement of DNA adducts provides structural confirmation of the analyte 
during analysis, without extensive labor or use of radioactivity.  There are several 
reports of LC-MS methods for platinum-DNA intrastrand adducts; however, each 
published report lacks an internal standard, which is essential for accurate and 
reproducible quantification (55, 56).  An internal standard is an important tool for 
mass spectrometry.  Our laboratory uses stable isotope labeled compounds for 
internal standards.  Using stable isotopes allows the use of a standard that has an 
identical chemical structure to the analyte of interest, the only difference being an 
increased final mass.  We then use our internal standard to add a known amount of 
adduct prior to each sample work-up and therefore have a control for error or loss in 
processing.   During mass spectrometric quantitation, the internal standard has an 
identical fragmentation pattern and retention time as the analyte. 
In summary, the most recent antibody assay is able to detect CP-d(GpG) or 
CP-d(ApG) in individual cells, however cross reactivity prevents this from being a 
specific method for adduct quantification.  32P-postlabeling is very sensitive and can 
quantify specific platinum DNA adducts with a limit of detection of 1 adduct per 108 
nucleotides.  However its use of radioactivity, lack of internal standard and inability 
to provide structural conformation limit its usefulness.  Atomic absorption 
spectroscopy measures only total platinum and requires large amounts of DNA 
and/or a high concentration of platinum for consistent quantification.  ICP-MS also 
measures total platinum and is more sensitive than AAS with a limit of detection of 1 
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adduct per 106 nucleotides.  However optimal sensitivity requires the use of a clean 
room.  Finally, previously published LC-MS methods for platinum DNA adducts have 
not utilized an internal standard.  Due to the technical limitations listed for each 
method, previously obtained data on cisplatin distribution and formation of 
intrastrand CP cross links in vivo may be insufficient to draw valid conclusions.  To 
advance our understanding of the formation and distribution of cisplatin cross links in 
different organs and within tissues (tumor vs. non-tumor) a stable isotope dilution 
mass spectrometry method was established for the accurate quantification of 
cisplatin derived 1,2 intrastrand cross links. 
 
1.5  Potential Role of Platinum-DNA Cross Links upon Acquired Resistance 
Currently, the complete mechanism leading to acquired resistance of cisplatin 
is not known.  However, the generally accepted intracellular mechanisms leading to 
cisplatin acquired resistance include: increased detoxification by thiols (e.g. 
glutathione, metallothionein), improved repair of and tolerance to nuclear lesions, 
and increased uptake/decreased efflux (diminished accumulation) of cisplatin.  Using 
our UPLC-MS/MS method to quantitate CP-d(GpG) adducts, we can further study 
the mechanism related to the improved repair and tolerance to these nuclear 
lesions.   
The ability to measure the density of specific adducts, using doses of cisplatin 
that are closer to those being used in the clinic will provide stronger rationale during 
the elucidation of the mode of action for efficacy and resistance.  We chose to focus 
our in vitro studies upon ovarian carcinoma resistance.  A review by Helm and 
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States tells us that most women are not diagnosed until the disease has already 
metastasized from the ovaries and ovarian cancer is associated with an overall 5 
year survival of little more than 50% (57).  Cisplatin has been the most effective 
therapy of ovarian cancer for the last 4 decades.  Women with intrinsically resistant 
tumors have a very poor prognosis.  Even though the majority of patients initially 
respond to platinum chemotherapy, many will ultimately develop disease that 
acquires resistance to cisplatin.  
Several models, other than ovarian carcinoma, exist for the study of cisplatin 
resistance.  Therefore in this section, we present selected studies, which use 
platinum DNA adduct formation as one endpoint.  One group treated sensitive and in 
vitro acquired resistance human small-cell lung carcinoma cells lines for 4 hours with 
166-500 µM cisplatin (58).  They found a correlation between resistance factor and 
level of glutathione.  Also, a dose-related trend was observed for the level of Pt-DNA 
binding, Pt-GG adduct content and amount of interstrand cross links.  Atomic 
Absorption Spectroscopy was utilized to determine the amount of total platinum, as 
well as the amount of CP-GG adduct after digestion and separation by Mono Q 
column, that required 1x107 and 5x107  cells, respectively, for quantitation.  Their 
overall conclusion was that a glutathione-induced decrease of reactive platinum in 
resistant cells was responsible for the lower net platination and therefore reduced 
toxic Pt-DNA adduct formation.  In 1996, Johnson et al treated sensitive and 
resistant human hepatoma cell lines for 4 hours using 0-200 micromolar cisplatin 
(59).  When comparing cisplatin efflux, total Pt-DNA adduct and interstrand cross 
link formation they found decreased intracellular accumulation to be the major 
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cisplatin resistance mechanism for hepatoma cells.  Vendrik et al studied cisplatin 
sensitivity and resistance in tumor and kidney tissues from LOU/M rats, in which an 
IgM immunocytoma cell line was grown (60).  These rats were treated intravenously 
with 1mg/kg cisplatin.  After 24 hours they noted a significant decrease in platinum 
content and in adducts of tumors, but not in the kidney.  However, once the results 
were corrected for dilution due to continued tumor growth after the initial dosing, it 
was determined that the mechanism of resistance was not likely due to differential 
CP uptake or efficiency of adduct formation/repair.  While the authors, during their 
investigation excluded several possible mechanisms, they did not suggest a specific 
mechanism for resistance in their model system.  Most recently, Fokkema et al. 
studied this phenomena using human germ cell and small-cell lung cancer cell lines, 
which were either sensitive, intrinsically resistant or had acquired resistance (61).  In 
this study, platinum-DNA adducts were measured immunohistochemically using an 
antibody that recognized CP-d(GpG) and the interstrand cross links.  Analysis of the 
data showed no differences in initial Pt-DNA adduct levels between any of the cell 
lines.  This suggests that the platinum resistance in these cell lines is based on 
adduct tolerance or increased repair.  Looking at all of these studies, one can see 
why there has been no agreement as to the cause of cisplatin resistance.  It may be 
that the mechanism of resistance is different based on tissue and/or tumor type.  
Several studies have shown that expression of genes, such as ERCC1 and 
BRCA1, which affect the repair of Pt-DNA adducts, is altered in cells with differing 
resistance to platinum chemotherapeutics (62-66).  One such study measured Pt-
DNA adducts as well as ERCC1 expression in resistant human carcinoma cell lines 
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after treating with lactacystin, a selective inhibitor of the ubiquitin pathway and 
degradation of proteins by the proteasome (67).  Treatment with lactacystin 
increased cisplatin toxicity, enhanced DNA platination and decreased repair of 
cisplatin-DNA adducts.  Also, lactacystin dramatically reduced the steady-state 
mRNA expression and the rate of transcription of the DNA repair gene ERCC1.  This 
response to lactacystin ultimately shows that ERCC1 and BRCA1 expression is 
likely to be higher with increased cisplatin resistance.  However in each of these 
studies, atomic absorption was used to measure repair/removal of Pt-DNA adducts.  
As previously discussed this technique measures total platinum and is not sensitive 
enough for use at clinically relevant levels of treatment.  Therefore, newer 
techniques would be required to quantify platinum DNA-adduct formation in order to 
test this hypothesis through clinical studies.  Many proteomic studies of platinum 
resistance in gynecologic cancer have also been performed (68-70).  In these cases, 
correlations of proteins such as ALD1 and PCNA (using mRNA expression) and 
resistance have been made, but without taking into account Pt-DNA adduct 
formation or repair.  To elucidate the role of Pt-DNA adduct formation in acquired 
resistance to CP, we have measured Pt-DNA adducts formed at various doses and 
time points in ovarian carcinoma cell lines selected for their sensitivity (A2780) or 
cell culture acquired resistance (A2780/CP70) to platinum therapy.  
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1.6  Potential Role of Platinum-DNA Cross Links upon Genetic Response to 
Cisplatin 
1.6.1  Genetics and Cisplatin 
Because the human population is genetically diverse, it is possible for 
individuals to have different responses to pharmaceutical agents.  One such genetic 
difference is a polymorphism, or multiple alleles of a gene within a population, which 
can express different phenotypes.  In our case, examples of phenotypes could be 
sensitivity or resistance to cisplatin treatment.  Patterns of single nucleotide 
polymorphisms (SNPs) can be used to identify haplotypes or sets of closely linked 
genetic markers present on one chromosome, which tend to be inherited together.  
Haplotype mapping can then be used to find quantitative trait loci (QTLs) or regions 
of DNA that are associated with a particular phenotypic trait.  These QTLs can be 
used to identify candidate genes, which may be responsible for a phenotype.  
Through techniques such as QTL mapping and gene expression profiling, 
pharmacogenomics researchers are studying drug related phenotypes, so that 
personalized medicine becomes a reality.   
 SNPs of several genes, such as ERCC1, BRCA and GST-P1, have been 
suggested to have an effect on the efficacy of cisplatin therapy.  In one study, cell 
lines from people of European or African descent were used to identify genetic 
variants and gene expression contributing to cisplatin-induced cytotoxicity (71).  
Using their whole genome approach, they found 17 representative SNPs that 
contributed to cisplatin-induced cytotoxicity by affecting expression of 26 gene in 
both populations.  Even though SNPs are being identified, QTL mapping has not 
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been widely done for cisplatin.  A literature search yielded only two papers in this 
area.  One used yeast as a model system to study the genetic variation in the 
cysteine biosynthesis pathway (72).  The other paper used lymphoblastoid cells, 
which they ultimately found to be unsuitable for use in QTL mapping (73).  In the 
latter study, their determination that lymphoblastoid cells are not suitable is of 
concern because the HapMap project is comprised mostly of this cell type.  
 
1.6.2  Total Body Distribution Animal Studies 
Only two total body distribution studies have been identified which use 
cisplatin. These studies performed with mice or dogs use radiolabeled cisplatin or 
measured total platinum by atomic absorption spectroscopy and have shown the 
highest concentration of cisplatin in the kidney (74, 75).  This is not surprising 
because of the nephrotoxicities that have been observed during treatment, as well 
as the kidney being the major excretory organ for this compound.  However, in these 
studies high amounts of cisplatin were also observed in the liver, even though no 
significant liver toxicity was reported (74, 75).  This may be due to the high 
concentration of glutathione and other thiols in the liver, which may bind cisplatin as 
a mechanism of detoxification.  There were also measureable levels of platinum 
found in other tissues, including the gastrointestinal tract.  
 
1.6.3  Clinical Studies---Pharmacogenetics 
Variability of individuals in the toxicity and efficacy of chemotherapeutic 
agents has been observed in the clinic (76-78).  Dr. Haider Ali, under the direction of 
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Dr. David Threadgill, has developed a model to study these phenomena using a 
panel of 8 strains of inbred mice and 7 chemotherapeutic agents, one of which is 
cisplatin.  Accurate quantification of Pt-DNA adducts is needed to understand the 
relationship between adduct accumulation and gene expression.  As mentioned in 
the previous section, animal distribution studies show the highest concentration of 
cisplatin in the kidney, show high levels in the liver and were able to detect some 
platinum in the gastrointestinal tract.  Therefore in our study, we have used liver, 
colon and kidney of the same murine strains to determine the molecular dosimetry of 
intrastrand CP-d(GpG) cross links.  The ultimate goal being to directly correlate the 
burden of Pt-d(GpG) adducts in tissues using our assay to the gene expression data 
previously obtained using the same study design.  This comparison will allow the 
discrimination between species-to-species differences in DNA damage response 
and in biodistribution of cisplatin. 
 
1.7  OBJECTIVE OF DISSERTATION RESEARCH 
Platinum chemotherapeutics are used in the treatment of lymphoma, ovarian 
carcinoma, breast and colorectal cancer.  Cisplatin is an effective anti-cancer agent.   
However, its use is hindered by adverse effects and the development of resistance.  
The mode of action for the efficacy and adverse effects are poorly understood.  
Cisplatin is known to bind to cellular nucleophiles, such as DNA and proteins.  
Binding to DNA results in the formation of intra- and interstrand cross links, which 
are repaired to some extent by nucleotide excision repair.  The goal of this work is to 
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study the role of cisplatin-DNA intrastrand cross links in acquired resistance and 
different genetic profiles.  
The 1,2 guanine-guanine intrastrand adduct is the most prevalent adduct 
formed when DNA is reacted with cisplatin.  Many studies have examined the role of 
cisplatin adducts upon toxicity, however the methods available often measured total 
platinum instead of directly quantifying individual adducts.  Furthermore, these 
methods required more sensitivity to enable data collection during experiments that 
utilize moderate to low doses of cisplatin.  Our hypothesis is that the density of 
intrastrand CP-d(GpG) cross links will serve as a useful biomarker for efficacy and/or 
toxicity of cisplatin. 
 
1.7.1  Specific Aims 
1. To develop an ultra sensitive and specific mass spectrometry method for 
characterization and quantification of the cisplatin 1,2 d(GpG) intrastrand adduct. 
2.  To determine the relationship between acquired resistance and formation and 
persistence of the CP-d(GpG) adducts using sensitive (A2780) and resistant (CP70) 
ovarian carcinoma cell lines. 
3.  To determine the density of CP-d(GpG) adducts in kidneys, livers, and colons 
obtained from eight strains of inbred mice.  
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FIGURES 
 
 
Figure 1.1 
Chemical Structure of Cisplatin 
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Figure 1.2 
Platinum-DNA Cross Links of Cisplatin. 
Underlined bases indicate bound cisplatin.  
 
1,2 Intrastrand GG [CP-d(GpG)] 
          TTAGGTCTCT 
AATCCAGAGT 
 
 
1,2 Intrastrand AG [CP-d(ApG)] 
TCTAGTTCTA 
 AGATCAAGAT 
 
 
1,3 Intrastrand GG (CP-GNG) 
TCTGTGCAAC 
AGACACGTTG 
 
 
Interstrand GG (dG-CP-dG) 
TTGATCATAT 
AACTTGTATA 
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CHAPTER 2 
 
DEVELOPMENT OF AN ULTRA PERFORMANCE LC/MS METHOD TO QUANTIFY 
CISPLATIN 1,2 INTRASTRAND GUANINE-GUANINE ADDUCTS 
 
This paper has been published and therefore is reproduced with permission 
from [Baskerville-Abraham IM, Boysen G, Troutman JM, Mutlu E, Collins L, deKrafft 
KE, Lin W, King C, Chaney SG, Swenberg JA. Development of an Ultra 
Performance LC/MS Method to Quantify Cisplatin 1,2 Intrastrand Guanine-Guanine 
Adducts. Chem. Res. Toxicol. Article ASAP, DOI: 10.1021/tx800481j]  Copyright 
[2009] American Chemical Society.  All method development, adduct quantification 
and cell culture experiments mentioned herein were performed by Irene M. 
Baskerville-Abraham.  
 
2.1  Abstract 
Platinum chemotherapeutic agents have been widely used in the treatment of 
cancer.  Cisplatin was the first of the platinum based chemotherapeutic agents and 
therefore has been extensively studied as an anti-tumor agent since the late 1960s. 
Because this agent forms several DNA adducts, a highly sensitive and specific 
quantitative assay is needed to correlate the molecular dose of individual adducts 
with the effects of treatment.  An ultra performance liquid chromatography tandem 
mass spectrometry (UPLC-MS/MS) assay for quantification of 1,2 guanine-guanine 
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intrastrand cisplatin adducts [CP-d(GpG)], using 15N10 CP-d(GpG) as an internal 
standard, was developed.  The internal standard was characterized by MS/MS and 
its concentration was validated by ICP-MS.  Samples containing CP-d(GpG) in DNA 
were purified by enzyme hydrolysis , centrifugal filtration and HPLC with         
fraction collection prior to quantification by UPLC-MS/MS  in the selective reaction 
monitoring (SRM) mode (m/z 412.5?248.1 for CP-d(GpG); m/z 417.5?253.1 for 
[15N10] CP-d(GpG)).  Recovery of standards was >90% and quantification was 
unaffected by increasing concentrations of calf thymus DNA.  This method utilizes 
25 µg of DNA per injection.  The limit of quantification was 3 fmol or 3.7 adducts per 
108 nucleotides, which approaches the sensitivity of the 32P postlabeling method for 
this adduct.  These data suggested that this method is suitable for in vitro and in vivo 
assessment of CP-d(GpG) adducts formed by cisplatin and carboplatin. 
Subsequently the method was applied to studies using ovarian carcinoma cell lines 
and C57BL/6J mice to illustrate that this method is capable of quantifying CP-
d(GpG) adducts using biologically relevant systems and doses. The development of 
biomarkers to determine tissue-specific molecular dosimetry during treatment will 
lead to a more complete understanding of both therapeutic and adverse effects of 
cisplatin and carboplatin.  This will support the refinement of therapeutic regimes 
and appropriate individualized treatment protocols. 
 
2.2  Introduction 
Platinum chemotherapeutics are used in the treatment of many types of 
cancer including breast, ovarian carcinoma, colorectal and metastatic cancers. The 
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first generation of platinum chemotherapeutics, cis-diamminedichloroplatinum II 
(cisplatin), is an effective treatment for several cancers.  The anticancer activity of 
cisplatin is attributed in part to the formation of inter- and intrastrand cross links in 
DNA, which inhibit gene transcription and DNA replication, thereby blocking protein 
synthesis and cell proliferation (1-3).  Unfortunately, cisplatin treatments have been 
accompanied by several side effects, such as neuropathy, gastrointestinal and renal 
toxicity. Recently, capacity for repair of cisplatin adducts has been linked to the 
severity of peripheral neuropathy in patients (4). Additionally, the development of 
cisplatin resistance prevents its use in some cancer patients.   
Cisplatin is an inorganic compound in which the platinum atom is bound to 
two amine groups and has two chloride leaving groups.  Cisplatin undergoes a non-
enzymatic conversion in physiologic solutions to active derivatives via displacement 
of chloride leaving groups (5). The activated cisplatin binds to DNA forming mono 
adducts, which ultimately form inter- and intrastrand cross linking DNA adducts.    
The cisplatin derived 1,2 guanine-guanine intrastrand [CP-d(GpG)] cross links are 
the most prevalent, compromising ~65% of the adducts formed in vivo (5-8). Since 
DNA adducts are excellent biomarkers for internal dose, many researchers have 
attempted to evaluate the role of Pt-DNA adducts in vivo.   Common methods used 
to measure Pt-DNA adducts include antibody probes, 32P postlabeling, atomic 
absorption and mass spectrometry.  Unfortunately, antibody based assays are prone 
to false positives due to cross reactivity and have a non-linear responses (9-11) and 
32P postlabeling methods, while able to detect as little as 0.087 fmol adduct per µg 
DNA, are labor intensive, utilize radioactivity and both methods do not provide 
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structural confirmation of adducts (12,13).  Atomic absorption spectroscopy 
measures total platinum, but lacks sufficient sensitivity for routine clinical application 
(14-18). Inductively coupled plasma mass spectrometry (ICP-MS) also measures 
total platinum with higher sensitivity, allowing application to clinical samples. One 
group has reported an ability to approach the sensitivity of the 32P postlabelling 
method using ICP-MS. However, they further reported that this level of sensitivity 
cannot be obtained with the addition of HPLC speciation, which is necessary for 
quantification of the individual, adducts. (19). Previously, a capillary HPLC-ICP-MS 
method was reported to measure CP-d(GpG) adducts specifically; this method 
reported a LOQ of ~ 1 adduct per 106 nucleotides, which is insufficient to measure 
samples treated with <500 µM cisplatin. (20).  Reported in the literature are 
mutagenesis assays with <10 µM cisplatin; therefore, greater sensitivity is needed to 
ensure direct comparisons of the formation and/or persistence of individual cisplatin 
adducts and the induction of mutations. LC-MS provides structural confirmation of 
the DNA adducts, without extensive labor or the use of radioactivity.  There are 
some reports of LC-MS methods for platinum-DNA intrastrand adducts; however, 
each published report lacks an internal standard, which is essential for accurate and 
reproducible quantification (21,22).  
Our method utilizes an internal standard and approaches the sensitivity of the 
32P postlabeling method with a limit of quantification (LOQ) of 0.12 fmol CP-d(GpG) 
per µg DNA or 3.7 adducts per 108 nucleotides, requiring only 25 µg of DNA on 
column.  To advance the understanding of the formation and distribution of cisplatin 
DNA lesions in vitro and in vivo, we report the development of a highly sensitive 
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stable isotope dilution mass spectrometry method for the accurate quantification of 
CP-d(GpG) cross links. 
 
2.3  Experimental Procedures 
Caution: Cisplatin is carcinogenic and should thus be handled in an approved 
laboratory fume hood, and personal protective equipment (i.e., gloves and lab coat) 
should be worn.  
 
2.3.1  Chemicals    
Unless otherwise stated, all chemicals and enzymes were purchased from 
Sigma-Aldrich (St. Louis, MO).  All solvents were HPLC grade and were purchased 
from Fisher Scientific (Pittsburgh, PA), along with Gentra PureGene components for 
DNA isolation.   The unlabeled oligonucleotide was prepared by Operon (Huntsville, 
Alabama). The heavy labeled oligonucleotide used in the synthesis of the internal 
standard was made by Silantes GmbH (Munich, Germany).  Reagents for cell 
culture studies were purchased from GIBCO Invitrogen (Carlsbad, California), with 
the exception of the Fetal Bovine Serum, which was purchased from Sigma-Aldrich 
(St. Louis, MO).   
 
2.3.2 Preparation of CP-d(GpG) Analyte Standard  
 An analyte standard was synthesized for optimization and standardization 
during method development.  All platination reactions were carried out with 40 mM 
aquated derivatives of the platinum complex obtained by overnight stirring in the 
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dark at room temperature of a solution containing cisplatin and 1.98 equivalents of 
silver nitrate.  Solution was then filtered through a 0.2 µm Gelman Acrodisk CR 
PTFE syringe filter (Fisher), and 10 µL aliquots stored at -80° C.  Immediately before 
each experiment, an aliquot of cisplatin solution was thawed at 50° C for 10 min and 
diluted (1:40 volume ratio) with HPLC water, taking care to avoid light exposure. 
Diluted aquated cisplatin and 2'-deoxyguanylyl (3',5')-2'-deoxyguanosine (4:1 molar 
ratio) were incubated at 37° C for 24 h. 
HPLC clean-up was performed using an Agilent 1100 HPLC with a 
Phenomenex Clarity 3µ Oligo-RP (100x4.6mm) column and a Hewlett Packard 
1040A photodiode array detector.  A gradient of 100 mM triethylamine acetate 
(TEAA) (Buffer A1) and 100% methanol (Buffer B) was operated at 1 mL/min, 
starting at 0% B with linear increases to 30% B by 15 min and 70% B by 16 min, 
followed by a decrease to 0% B by 17 min and a 3 min column re-equilibration. All 
peaks thought to contain cisplatin cross links were collected and aliquots were 
characterized by UV on a Thermo BioMate 5.  Standards were quantified using the 
extinction coefficient for d(GpG) (ε260=21, 600) (23,24). The stock solutions were 
stored in 10 mM ammonium acetate pH 4 at -20° C. Dilutions of the stock were 
made in 10 mM ammonium acetate for MS analyte standard curves.  
Inductively coupled plasma mass spectrometry (ICP-MS) was utilized to 
confirm the concentration of standards that had been estimated from the UV 
absorbance and extinction coefficient.  Samples of 10 to 96 pmol, as measured by 
UV, were diluted to 4 mL in 2% nitric acid in HPLC water for measurement by ICP-
MS.   
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The analytical standards were characterized by LC-MS as follows:  a 
Phenomenex Luna 3µ C18(2) column (2.0x150 mm) was operated using a linear 
gradient of 10 mM ammonium acetate plus 0.1% acetic acid (pH 4.5) (Buffer A2) to 
50% methanol (Buffer B) over 28 min and returning to 0% methanol at 30 min. The 
positive and negative full scan electrospray mass spectra (m/z 100-1000) were 
acquired on a Finnigan TSQDeca ion trap mass spectrometer.  
 
2.3.3 Preparation of 15N10 CP-d(GpG) Internal Standard 
An internal standard was synthesized to ensure accurate and precise 
quantification of cisplatin adducts.  To determine appropriate ratios of incubation 
times for platination, an unlabeled oligonucleotide was purchased from Operon with 
the sequence ACTGGTCATGGTACTGGT. Once optimal conditions were 
established, Silantes was contracted to synthesize a 15N fully labeled oligonucleotide 
of the same sequence.  15N labeling was confirmed by mass spectrometry after 
enzymatic hydrolysis.  This 15N labeled oligo was rehydrated in HPLC water for a 
final concentration of 0.55 nmol /µL.  To make the internal standard, 60 nM of the 
oligo was reacted with aquated cisplatin in HPLC water utilizing a drug to oligo molar 
ratio of 24:1 at 37 °C for 72 h in the dark.  
To separate the adducted nucleotide from the surrounding unmodified 
nucleosides, the samples next underwent an enzymatic hydrolysis based upon the 
method previously reported by Eastman (25).  Briefly, 50 µg aliquots of platinated 
oligo, 320 µL of 50mM sodium acetate/10mM magnesium chloride and 0.02 kunitz 
unit of DNase I were incubated for 4h at 37 °C, next 2 units of nuclease P1 were 
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added and incubation continued for 16-20h. Finally 41µL 1M Tris-HCl pH 9 and 5 
units alkaline phosphatase were added and incubation continued for 4h, followed by 
Microcon-3 spin columns (Millipore) to remove enzymes. All incubations were 
performed in the dark. Sample enrichment and characterization were performed as 
described above for the analyte CP-d(GpG). After concentration was determined by 
UV and confirmed by ICP-MS, 500 µL aliquots containing 100 fmol per µL in buffer 
A2 were stored at -80° C for use as internal standard (Table 1).   
 
2.3.4 Platination and Preparation of Calf Thymus DNA 
 Calf thymus DNA (ctDNA) was used to validate the UPLC-MS/MS method.  
Sigma ctDNA was rehydrated to 1 mg/mL aliquots and stored at -20° C.  ctDNA (150 
µg) was reacted with 100 nM aquated cisplatin and brought to a total volume of 1mL 
in deionized H2O at 37 °C for 24 h.  DNA was enzymatically digested in the same 
manner as the internal standard.  Because of the increased number of samples, 
solid phase extraction columns were initially used for sample enrichment instead of 
HPLC.  
Solid phase extraction (SPE) clean-up was performed using both strong 
cation exchange (SCX) and C18 columns. After enzymatic hydrolysis, samples were 
adjusted to pH 3 by the addition of 0.8 vol 50 mM HCl.  Next, LiChrolut SCX columns 
(VWR) were placed on a vacuum manifold, conditioned with two additions each of 1 
mL water, 1 mL methanol, and 1 mL water, and then equilibrated with 1 mL 50 mM 
Tris HCl pH 3.  The samples were applied to the columns, which were then washed 
four times with 2 mL 5 mM sodium formate pH 6.  Platinated adducts were then 
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eluted with two additions of 0.5 mL 250 mM ammonium hydroxide.  To remove salt 
prior to MS analysis, Maxi-Clean 300 mg C18 cartridges (Alltech) were utilized. First, 
the eluent was adjusted to pH 7 by addition of 130 µL 50 mM HCl.  Next, the C18 
cartridges were conditioned and equilibrated using two additions of  2 mL water, 2 
mL methanol, 2 mL 10 mM ammonium acetate.  The pH adjusted sample was then 
applied to the column, which was washed with three additions of 2 mL 10 mM 
ammonium acetate. Platinum adducts were eluted with two additions of 0.5 mL 10 
mM ammonium acetate in 50% methanol.  After solid phase extraction, enriched 
samples were dried via centrifugal lyophilization.  Samples were rehydrated using 10 
mM ammonium acetate pH 4 in 10% methanol, placed in vials for analysis, dried 
once again by centrifugal lyophilization and finally brought to identical running 
volumes through the addition of 40 µL 10 mM ammonium acetate pH 4.  Samples 
were then either stored at -80° C or immediately placed in the MS injector tray to 
begin adduct quantification.  During method development, we found that the CP-
d(GpG) adduct is most stable under specific conditions.  Unsuccessful attempts 
were made to perform loop injections using purified CP-d(GpG) with water and 
methanol as buffers.  It was ultimately determined that CP-d(GpG) was the most 
stable with a salt containing buffer at a between pH 4-4.5.  We achieved this using 
10mM ammonium acetate with 0.1% glacial acetic acid in place of water as a 
storage and running buffer.  Because of limited recovery during SPE (~20%), it was 
determined that HPLC with fraction collection was more suitable for sample 
purification after enzyme hydrolysis.   The changes in pH and multiple buffers 
required the use of strong cation exchange SPE followed by a C18 cartridge to 
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remove sodium salt prior to MS quantification. This may have affected the stability of 
the adduct, thereby reducing the overall recovery by SPE. 
 CP-d(GpG) was purified from DNA hydrolysate by HPLC fractionation utilizing 
an Agilent 1200 system consisting of a G1312B binary pump SL, a G1379B 
degasser, a G1316B thermostatted column compartment SL, a G1215C diode array 
SL, a G1367C/G1330B thermostatted high performance autosampler SL, and a 
G1364C/G1220B analytical scale fraction collector to separate adducts from 
unmodified nucleosides.  Therefore, a Phenomenex Clarity 3µ Oligo-RP (100x4.6 
mm) column, 10 mM ammonium acetate in 0.1% glacial acetic acid (Buffer A2) and 
methanol (Buffer B) were operated with a linear gradient for 30% B over 20 min, 
then to 70% B in 2 min and finally decreasing 0% B in 1 min and re-equilibration for 
2 min prior to the next injection.  Fractions containing platinum adducts were 
collected from 6.85 min to 8.85 min. Fractions were dried via centrifugal 
lyophilization and rehydrated using a mix of 50/50 Buffer A2 and B, placed in MS 
vials, and once again dried by centrifugal lyophilzation. Samples were either stored 
at -20° C or immediately rehydrated in 40 µL Buffer A2 for UPLC tandem mass 
spectrometric analysis.   
 
2.3.5 UPLC-MS/MS Method 
Quantitative LC-MS/MS data were obtained using a Waters Acquity UPLC 
coupled to a Thermo Finnigan TSQ Quantum Ultra triple-quadrupole mass 
spectrometer.  A heated electrospray ionization (HESI) interface was operated in 
positive ionization mode.   The analyzer was operated in selective reaction 
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monitoring (SRM) mode, monitoring the loss of phosphate, two deoxyriboses and 2 
amines from CP-d(GpG) (m/z 412.5 to 248.1, z=2) and [15N5]-CP-d(GpG) IS (m/z 
417.5 to 253.1, z=2). Samples were kept at 4° C during analysis, and the sample 
injection volume was 20 µL. An HSS T3 (2.1 mm x 100 mm; 1.8 µm) UPLC column 
(Waters) was conditioned with aqueous 0.1% glacial acetic acid (A3) and methanol 
(B) at a flow rate of 200 µL/min.  Cisplatin adducts were eluted with a linear gradient 
of 1-10% B over 10 min, then to 50% B in 1 min, followed by a 3 min re-equilibration 
at 1% B.  The LC flow was diverted to waste for the first 4 min of the gradient.  
Instrument conditions were optimized for maximum signal of CP-d(GpG) by direct 
infusion and on column injections of analyte standard.  MS settings were as follows: 
electrospray voltage ( 3000 V), capillary temperature (285 °C), HESI temperature 
(250 °C), sheath and auxiliary gas pressures (35 and 30 arbitrary units), collision 
energy ( 25 V), and Q2 collision gas pressure (1.5 mTorr).  
 
2.3.6  Quantification 
Analyte standard or 50 µg of platinated DNA was spiked with 500 fmol of 
Internal Standard and enzymatically hydrolyzed as described in the analyte standard 
section.  Samples were then processed by solid phase extraction columns or HPLC 
and prepared for MS quantification as described in the calf thymus DNA section. 
 
2.3.7  Inductively Coupled Plasma Mass Spectrometry 
Aliquots of analyte and/or internal standard using 10 to 96 pmol CP-d(GpG) 
were brought to a final volume of 4 mL in 2% nitric acid.  A Varian 820-MS 
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Inductively Coupled Plasma-Mass Spectrometer was used to determine Pt 
concentration.  Samples were introduced via a concentric glass nebulizer with a free 
aspiration rate of 0.4 mL/min, a Peltier-cooled double pass glass spray chamber, 
and a quartz torch.  A peristaltic pump carried samples from a SPS3 autosampler 
(Varian) to the nebulizer.  All standards and samples were in 2% nitric acid, 
prepared with milliQ water.  Prior to each experiment, optimization of the 
instrument’s operating parameters was performed using a tuning solution 
(Spectropure, Arlington, TX) diluted to 5 ppb each of Ba, Be, Ce, Co, In, Pb, Mg, Tl, 
and Th.  Ion optics and plasma parameters were optimized to maximize sensitivity 
while minimizing interferences.  Pt standards were prepared by serial dilution of a 
solution containing 10 ppm Pt (Inorganic Ventures Inc., Lakewood, NJ).  A four-point 
calibration curve was made over a concentration range of 0.5-8 ppb Pt.  The two 
most abundant isotopes of Pt were monitored, 194Pt (33.0% abundance) and 195Pt 
(33.8% abundance).  A 200 ppb dilution of the tuning solution was used for 
monitoring 115In as the internal standard.  Data acquisition was done using peak 
hopping with a dwell time of 50 ms, one point per peak, 20 scans/replicate, and five 
replicates per sample.   
 
2.3.8  Treatment of Ovarian Carcinoma Cells 
Human ovarian carcinoma cell lines A2780 and A2780/CP70 were graciously 
provided by Dr. Thomas C. Hamilton (Fox Chase Cancer Center). The parent cell 
line A2780 is sensitive to cisplatin, while the A2780/CP70 line exhibits stable 
cisplatin resistance developed from chronic exposure to increasing concentrations of 
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cisplatin as described previously (26). Cells were maintained as monolayers in RPMI 
1640 medium supplemented with 10% fetal bovine serum (heat inactivated), 2 µM L-
glutamine, insulin (0.25 units/mL), penicillin (100 units/mL), streptomycin (100 
µg/mL), and amphotericin B (0.25 µg/mL) at 37° C and 5% CO2.   
 In both the dose-response and time-course studies, 2 x 106 cells were plated 
in T175 flasks and allowed to grow for three days.  The growth medium was 
removed and cells were rinsed twice with PBS before serum-free medium plus 12.5-
250 µM cisplatin or PBS was applied.  After 1 h incubation, the cisplatin-containing 
medium was removed and the cells for the dose response were trypsinized and 
collected.  Cells for the time-course assay were rinsed with PBS and complete 
medium reapplied for an additional 3 or 7 h before trypsinization and collection.  
DNA was isolated from cells with the Gentra PureGene cell kit, as recommended by 
the manufacturer. 
 
2.3.9  Study Conditions for C57BL/6J Mice 
Male C57BL/6J mice (n=3) were injected i.p. with 7 mg/kg cisplatin.  On days 
1 and 3 after injection, the mice were euthanized by carbon dioxide anoxia; portions 
of the kidney, liver, and colon were snap-frozen and stored in a –80° C freezer, after 
removing sections for histopathology.  Numerical scale of histology scoring and 
description is as follows:  0= absent or no significant lesions (NSL), 1= Minimal 
lesions (<5%), 2= Mild lesions (5-25%), 3= Moderate lesions (25-50%), 4= 
Marked/severe lesions (>50%). 
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We used the FDA’s dose calculator (http://www.fda.gov/cder/cancer/animalframe.htm) 
to better understand how the cisplatin dose in our mouse study (7 mg/kg) relates to 
a low human dose (50 mg/m2) received in the clinic.  Using an adult mouse weighing 
20 g, the total dose at 7 mg/kg cisplatin received would be 0.14 mg, which is equal 
to 21.11 mg/m2.  Conversely, a dose of 50 mg/m2 would require 0.33 mg or 16.58 
mg/kg. 
 
2.3.10  DNA Isolation from Tissues 
DNA was extracted using Gentra PureGene kit reagents with a significantly 
modified protocol. Because of reduced amount of colon tissue available for 
processing, all volumes in the procedure below were reduced by half when isolating 
DNA from this tissue.  Briefly, frozen kidney (400 mg), liver (400 mg) or colon tissue 
(150 mg) were thawed in 6 mL ice-cold phosphate-buffered saline (PBS, pH 7.4). 
The tissue samples were homogenized with a Tehran homogenizer (Wheaton 
Instruments, Millville, NJ). After centrifugation at 1000 g for 15 min, the pellet was 
washed with 6 mL homogenization buffer. The nuclear fraction was collected by 
centrifugation and was reconstituted in 6 mL cell lysis buffer. Proteinase K (400 
U/mL, 150 μL) was added to the sample and incubated overnight at 4° C.  The 
following morning, samples were placed on ice. Proteins were then extracted by the 
addition of 2 mL protein precipitation solution followed by centrifugation at 2000 g for 
10 min and the collection of the supernatant. Nucleic acids were precipitated from 
the supernatant using 6 mL isopropanol. The nucleic acids were collected by 
centrifugation, rinsed with 6 mL of 70% ethanol, and allowed to air dry.  The nucleic 
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acid pellet was reconstituted in 6 mL cell lysis solution supplemented with RNAse A 
(0.8 KeU/mL, 27 µL) to digest RNA.  After 30 min incubation at 37° C, another 
protein precipitation was performed and supernatant collected.  DNA was 
precipitated using 6 mL isopropanol, collected by centrifugation and rinsed with 70% 
ethanol.  The DNA was resuspended in 400 µL HPLC grade water and its 
concentration and purity estimated by UV spectrometry. The DNA solution was 
stored at –80° C until CP-d(GpG) adduct analysis.  
 
2.4  Results 
2.4.1  Characterization of the CP-d(GpG) Analyte Standard 
The cisplatin 1,2 intrastrand guanine-guanine adduct (CP-dGpG) was 
characterized by UV and MS. Analyte standards were examined for purity after 
synthesis using full scan and SRM MS to ensure correct derivatization of our 
compound. Quantification of adducts was performed using a Waters Acquity UPLC 
coupled to a Thermo Finnigan TSQ Quantum Ultra MS.  Standard curves using the 
synthesized analyte and internal standards were run using the UPLC-MS/MS 
method shown in Scheme 2.1. 
Negative and positive ionization efficiencies were evaluated because CP-
d(GpG) adducts exist in solution as zwitterions caused by the negative phosphate 
and positive amine groups. The examination showed better ionization in the positive 
ion mode.  Also a platinum specific isotopic cluster consisting of 5 (2 major and 3 
minor) isotopes aided product identification (Figure 2.1). The MS/MS scans were 
originally performed in the positive ionization mode using several transitions to 
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account for the loss of the dRibpdRib moiety as well as one or two amines ([M-
dRibpdRib-NH2]+ or [M-dRibpdRib-2NH2]+ ) in both its singlet (m/1 824.0 to 513.1 or 
497.2) and doublet (m/2 412.5 to 256.5 or 248.1) states.  Figure 2.2 shows a 
representative chromatogram in which we measured both the singlet and doublet 
charge states.  Through the comparison of peak areas, it was determined that 
MS/MS quantification of the CP-d(GpG) adducts was most sensitive using the 
doublet charge state.  Additionally, the optimal fragmentation involved the loss 
dRibpdRib and two amines ([M-dRibpdRib-2NH2]+ ;analyte m/z 412.5 to 248.1).   
 
2.4.2  Synthesis and Characterization of 15N CP-d(GpG) Internal Standard 
An unlabeled oligonucleotide with identical sequence to the 15N labeled 
oligonucleotide was used in the determination of platination efficiency (as confirmed 
by 32P gels, data not shown) to ensure optimal synthesis of final 15N CP-dGpG 
adducts. Next, the internal standard was characterized in the same manner as the 
analyte. Figure 2.3 shows a positive MS full scan of the unlabeled internal standard 
after digestion and SPE clean-up.  After conditions of adduct synthesis had been 
optimized the 15N CP-d(GpG) internal standard was prepared accordingly. As 
expected, the internal standard was most sensitive in the doubly charged state 
(internal standard m/z=417.5) and shares the same optimal fragmentation as the 
analyte ([M-dRibpdRib-2NH2]+; internal standard m/z=417.5 to 253.1). 
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2.4.3  Method Accuracy and Precision 
A calibration curve was run using various concentrations of analyte standards 
and constant amount of 500 fmol internal standard.  Method precision was first 
assessed by processing four replicates of known concentrations of analyte standard 
by solid phase extraction.  Intraday precision (r2=0.99) was determined using 0, 5, 
10, 50, 100 fmol CP-d(GpG). Interpreparation precision (r2=0.99) was determined 
using replicates processed on separate days and run by MS on different days.  
Interday precision (r2=0.99) was determined using replicates processed on the same 
day and run by MS on different days. The limit of detection (LOD) was determined 
using solution of authentic standard CP-d(GpG).  The limit of detection with a signal 
to noise of >2 was 1 fmol CP-d(GpG)  per injection, therefore the limit of 
quantification (LOQ) was set to be 3 times the limit of detection (3 fmol CP-d(GpG) 
per injection) with a signal to noise of >6. Initially, UV measurements were used to 
determine the concentration of the analyte and internal standard.  ICP-MS was used 
to validate the platinum adduct concentration obtained by UV. Final standard 
concentrations were adjusted by a factor of 1.3 based upon ICP-MS data.  Table 2.1 
shows a comparison of the data obtained by each method. To determine the effect 
of DNA concentration on the quantification of CP-d(GpG), 0-200 µg calf thymus DNA 
was added to samples containing 100 fmol analyte and 500 fmol internal standard, 
and processed through the method. No effect of DNA concentration on the 
quantification of CP-d(GpG) was observed (data not shown).  Recovery experiments 
were also performed using 35, 140, and 700 fmol analyte standard when using the 
SPE sample enrichment process vs. no SPE enrichment.  Sample recovery with 
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SPE enrichment was ~20%, data not shown.  Later additional recovery experiments 
were performed using analyte standard prepared using HPLC with fraction collection 
vs. no HPLC enrichment.  Sample recovery increased to   > 90%, data not shown. 
 
2.4.4  Quantification of CP-d(GpG) in Calf Thymus DNA 
This method was validated using platinated calf thymus DNA that was diluted 
with blank calf thymus DNA.  Aliquots of 0, 25, 50, and 100 µg platinated calf thymus 
DNA were placed in eppendorf tubes with 500 fmol internal standard and the 
corresponding amounts of blank calf thymus DNA was added to bring the total 
amount per tube to 100 µg.  These samples were processed through the hydrolysis 
method using HPLC clean-up and total adducts were quantified by UPLC-MS/MS.  
As expected, a linear response was observed (Figure 2.4). 
 
2.4.5  Dose Response of Cisplatin Adducts in Ovarian Carcinoma Cells 
An isogenic pair of ovarian carcinoma cell lines (A2780 and CP70) which 
were originally created to mimic the process of acquired cisplatin resistance was 
used in our validated assay.  We observed a two fold difference between the 
sensitive A2780 and resistant CP70 cell lines, which was in line with previous 
estimates of relative adduct amounts in those two cell lines  (Figure 2.5)(27). 
 
2.4.6  Determination of CP-d(GpG) Adducts in Mouse Tissues 
The C57BL/6J mouse strain was used to demonstrate CP-d(GpG) 
accumulation in vivo after an i.p. injection with 7 mg/kg cisplatin.  Three days post 
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injection, the greatest amount of adducts were observed in the kidney, followed by 
the liver and colon (Table 2.2). In the same mice, histopathology slides of the kidney 
showed marked tubular nephrosis/apoptosis with moderate tubular 
vacuolation/degeneration, while the liver showed moderate centrilobular fatty change 
and the colon showed minimal crypt cell necrosis/apoptosis (Table 2.3). 
 
2.5  Discussion 
2.5.1  Method Development and Validation 
During the development of this method it was necessary to modify the sample 
clean-up procedure after enzymatic hydrolysis from solid phase extraction to HPLC.  
SPE was preferred because it allowed for a higher throughput processing of 
samples, and allowed several types of platinated adducts to be collected 
simultaneously.  However, increased recovery was important when considering our 
limit of detection as well as the reduced amount of adduct that may be formed when 
studying lower and biologically relevant doses of cisplatin.  Changing the method to 
utilize an HPLC clean-up with an autosampler and fraction collector, increased 
recovery from 20% to >90%.   
Atomic absorption has often been used to determine total platinum adduct 
levels in both in vitro and in vivo studies. ICP-MS, which like atomic absorption 
measures total platinum, has been reported to be more sensitive than atomic 
absorption (19). The oligonucleotide used for the synthesis of the internal standard 
was designed to form only the CP-d(GpG) adduct, unlike in vivo where other 
adducts such as CP-d(ApG) may also be formed during DNA platination.  To 
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validate the concentration of analyte and internal standard used in our assay, ICP-
MS was employed.  Using normal conditions, the lowest amount of CP-d(GpG) that 
could be measured was  11.3 pmol or 0.6 ppb Pt resulting in a relative standard 
deviation (RSD) of 5.6%.  To decrease error, 42.2 pmol or 2.1 ppb Pt was necessary 
for the RSD to decrease to 1.9%. Thus, we feel that 2.1 ppb represents the lower 
level for precise determination of CP-d(GpG) by ICP-MS.   
A capillary LC-MS/MS method for CP-d(GpG) adduct quantification was 
previously developed in our laboratory, which utilized an internal standard with a 
chemical structure close to, but not identical to that of the CP-d(GpG) adduct.  While 
it allowed the use of 10-fold less DNA than atomic absorption, the limit of 
quantification for this method was 3 pmol. Therefore, sensitivity needed to be 
improved 20- to 25- fold to determine the levels of platinum adducts in cell culture at 
physiologically relevant doses of cisplatin. Our current method has increased 
sensitivity by 1000-fold with a limit of quantification of 3 fmol.  The use of UPLC-
MS/MS in the SRM mode, coupled with the utilization of a chemically identical stable 
isotope internal standard, provides a higher level of specificity and accuracy of 
quantification than previous methods.    
 
2.5.2  Quantification of CP-d(GpG) in vitro and in vivo 
The method was applied to measure the formation of CP-d(GpG) in treated 
calf thymus DNA, as well as the accumulation of CP-d(GpG) adducts in ovarian 
carcinoma  cell lines (A2780, CP70) and in mice.  In treated calf thymus samples 
diluted with blank calf thymus DNA, a linear response was observed as expected.  
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Consequently, a study using an in vitro cell culture model allowed further insight as 
to whether this method could be used to determine CP-d(GpG) adducts at 
biologically relevant concentrations of cisplatin.  
The cisplatin sensitive A2780 and resistant CP70 cell lines had been shown 
to have a two-fold difference in adduct formation, but this determination was 
obtained when treated with >250 µM cisplatin (27), because previous methods were 
unable to measure specific platinum adducts at more biologically relevant levels of 
cisplatin and/or doses that allowed cells to continue to proliferate.  Investigators 
have commonly used adduct data obtained using toxic, but not necessarily 
pharmacologically relevant doses of cisplatin, and have assumed a linear 
relationship when making their conclusions.   The present UPLC-MS/MS method 
allowed analysis of CP-d(GpG) at more pharmacologically relevant doses and has 
shown that the dose response relationship remains linear at these lower doses of 
cisplatin.   
The studies were then extended to the analysis of CP-d(GpG) adduct levels 
in C57BL/6J mice that had received i.p. injections of  7 mg/kg, which is  ~21 mg/m2 
cisplatin.  Histopathology of the kidney, liver and colon showed treatment related 
effects and the method was able to quantify CP-d(GpG) adducts formed in those 
tissues on days 1 and 3. Reed et al. reported up to 0.248 fmol per microgram 
cisplatin intrastrand adducts [CP-d(GpG) and CP-d(ApG)] in blood samples obtained 
from testicular cancer patients which had been treated with 40mg/m2 cisplatin for 5 
days (28). If we assume that 75% of these adducts are CP-d(GpG) based upon the 
ratios of total cisplatin DNA adducts as reported by Fichtinger-Schepman we would 
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be able to quantify most of these adducts using our method (8).  More recently, 
Brouwers et al used ICP-MS to determine platinum levels in DNA extracts of 
peripheral blood cells from gastric cancer patients treated with 60 mg/m2 cisplatin 
during a 4 h infusion.  They were able to detect 0.182-16.6 fmol platinum per 
microgram DNA (19,29).  When measuring these same samples using 32P-
postlabelling they found 0.161-14.1 fmol CP-d(GpG) and 0-1.78 fmol CP-d(ApG) 
adducts per microgram DNA.  Together these data would suggest that our method 
would be able to quantify adducts in tissues obtained from patients undergoing 
cisplatin based chemotherapy. Recently, several groups have been using systems 
biology and functional genomics to gain information about inter-individual differences 
in drug toxicity (30-32). Studies are currently underway to link our DNA adduct 
results in mice with phenotypic anchoring of genomic data across multiple strains of 
mice. 
 
2.5.3  UPLC-MS/MS Method 
Cisplatin is an effective treatment for cancer, however due to neuropathy, 
gastrointestinal and renal toxicity, research has been performed to make less toxic 
analogues. One analogue, carboplatin, has more tolerable toxicity and has been 
shown to be comparable therapeutically in some cancers, while cisplatin was 
therapeutically superior in others (33). Because of the decreased toxicities, 
carboplatin is currently more commonly used in chemotherapeutic regimes. Both 
cisplatin and carboplatin bind to DNA and ultimately form chemically identical DNA 
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cross links.   Therefore, this assay can be used to detect the 1,2 guanine-guanine 
adducts formed by either compound.   
The 1,2 intrastrand guanine-guanine and adenine-guanine adducts comprise 
over 90% of the total adducts formed by cisplatin exposure (8,34). This method can 
also be expanded to include quantification of the 1,2 adenine-guanine adduct. 
However, this method is not suitable for the measurement of all cisplatin DNA 
adducts.  For instance, the 1,3 intrastrand guanine-guanine adduct and the 
interstrand guanine-guanine adduct once separated from the DNA backbone cannot 
be differentiated by mass spectrometry and therefore a different methodology would 
be needed for those adducts.  
In summary, the presented UPLC-MS/MS method has a limit of quantification 
of 0.12 fmol CP-d(GpG) per µg DNA or 3.7 adducts per 108 nucleotides.  This level 
of sensitivity approaches or equals that of 32P-postlabeling methods (13,35).  We 
have shown that we are able to measure adducts formed in vitro and in vivo at 
doses of cisplatin that are more relevant for use during biological studies of cisplatin 
instead of high dose toxicity studies previously required for adduct quantitation. As 
mentioned in the introduction, there have been several other methods developed to 
measure platinum-DNA adducts.  None of the previously published methods 
included an internal standard. During our studies we utilized 500 fmol IS based on 
our initial method development and cell culture studies, at which time in vivo adduct 
values were not certain.   In future clinical studies lower IS amounts could be used.  
Our internal standard has an identical chemical structure to our analyte of interest 
and differs by 10 mass units because of the stable isotope labeling of the guanines. 
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The use of an internal standard is necessary to correct for error that can be caused 
during sample preparation or due to differences in equipment sensitivity between 
runs.  Our method is the first to use a stable isotope labeled internal standard for 
mass spectrometric quantification of cisplatin-DNA adducts.   
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FIGURES 
 
 
 
 
 
 
 
Figure 2.1 MS Isotope Simulation of CP-d(GpG) 
There are three major masses for this adduct due to isotopes. 
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Figure 2.2   Representative SRM Ion Chromatograms comparing the Use of Singly 
(m/1) vs. Doubly (m/2) Charged State  
 
Representative SRM ion chromatograms comparing the use of singly (m/1) vs. 
doubly (m/2) charged state during MS/MS analysis of CP-d(GpG) analyte (A and B) 
and internal standards (C and D).  A and C show MS/MS fragmentation in the singly 
charged state, while B and D show MS/MS fragmentation in the doubly charged 
state.  The chromatogram has been cropped as no other quantifiable peaks are 
observed. 
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Figure 2.3   Full scan positive ion MS spectrum m/z 450 – 850  
 
Full scan positive ion MS spectrum m/z 450 – 850 showing the in source 
fragmentation of CP-d(GpG).  The main ions observed were [M-NH2]+ m/z 807.1, [M- 
dRibpdRib-NH2]+ m/z 497.2, [M- dRibpdRib]+ m/z 513.1, and [M-deoxyribose]+ m/z 
708.1. All fragment ions contained the Pt characteristic isotopic profile.  
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                                    SCHEMES 
 
 
 
 
 
 
Scheme 2.1   Preparation and quantification of CP-d(GpG) adducts by UPLC-
MS/MS.   
 
Cisplatin treated DNA is isolated.   Next, internal standard is added and enzyme 
hydrolysis is performed.  Following hydrolysis, solid phase extraction or HPLC 
enrichment separates the platinated adduct from nucleosides, enzymes and 
sodium salts.  Finally, the CP-d(GpG) adduct is quantified by UPLC-MS/MS. 
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TABLES 
 
 
 
 
 
          
  pmol CP-d(GpG) ppb Pt pmol CP-d(GpG) ICP-MS 
Sample 
type [UV] ICP-MS [ICP-MS]  %RSD 
IS 13 0.7 13.2 5.5 
AS 1 9.6 0.6 11.3 5.6 
AS 2 57.6 2.1 42.2 1.9 
AS 3 96 3.5 72.6 1.5 
  *n=3    
 
Table 2.1  Validation of Standard Concentrations by UV and ICP-MS.  
 
Samples were prepared in triplicate for ICP-MS I n 2% nitric acid based upon 
initial UV concentrations. 
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BL6 1 
(fmol/ µg DNA) 
BL6 2 
(fmol/ µg DNA) 
BL6 3 
(fmol/ µg DNA) 
Average 
(fmol/ µg DNA) 
Kidney 53 57 67 59±7 
Liver 21 22 16 20±3 
Colon 3 6 5 5±2 
 
Table 2.2  Quantification of CP-d(GpG) in C57BL/6J mice Three Days post i.p. 
injection of 7mg/kg Cisplatin 
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  BL6 1 BL6 2 BL6 3 
Liver    
 - hepatic necrosis 0 0 0 
 - centrilobular fatty change 3 3 2 
 - inflammation 0 0 0 
Colon    
 - crypt necrosis/apoptosis 1 1 1 
Kidney    
 - tubular nephrosis/apoptosis 4 4 3 
 - tubular vacuolation/degeneration 3 3 2 
 - tubular mineralization 2 0 2 
 - inflammation  0 0 0 
                              0 = absent or no significant lesions 
                              1= minimal lesions 
                              2= mild lesions 
                              3= moderate lesions 
                              4= marked lesions 
 
Table 2.3  Histopathology of C57BL/6J Mice Three Days post i.p. injection of 7mg/kg 
Cisplatin 
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CHAPTER 3 
STRAIN DIFFERENCES IN TOXICITY AND MOLECULAR DOSIMETRY 
FOLLOWING CISPLATIN ADMINISTRATION TO MICE 
 
3.1  Introduction 
Cisplatin was approved for clinical use in the late 1970s and remains an 
efficacious chemotherapeutic agent.  However, it does not work for every person or 
for every cancer.  Some patients who undergo platinum-based chemotherapy have 
intrinsic or acquired resistance to treatment.  Several of the hypotheses regarding 
the development of resistance to cisplatin chemotherapy have been discussed in the 
introduction of this thesis.  Our goal for this study was to evaluate strain differences 
in cisplatin toxicity and molecular dose of cisplatin adducts using the UPLC-MS/MS 
biomarker developed in Chapter 2.  In this way we can use CP-d(GpG) as a 
biomarker to determine the molecular dose of cisplatin adducts, allowing us to 
distinguish  between strain differences in which genetics affects sensitivity to Pt-DNA 
adducts from strain-related differences in the pharmacokinetics and 
pharmacodynamics of cisplatin.  Information about CP-d(GpG) adduct burden in 
specific tissues and strains may be essential for interpretation of gene expression 
studies aimed at ultimately identifying a phenotypic marker for cisplatin sensitivity.  
This information coupled with quantitative trait loci mapping and the sequencing of 
the human genome, could provide valuable information about why some individuals 
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are more responsive to platinum based chemotherapy and ultimately help 
researchers to design more individualized therapies for patients.   
 Because there has been variability in observed toxicity and efficacy of 
chemotherapeutic agents when used in the clinic, the major goal of 
pharmacogenomics is to develop individualized therapies for patients.  Dr. Haider 
Sayed Ali, under the direction of Dr. David Threadgill, developed a model to study 
these phenomena using a panel of 8 strains of inbred mice and 7 chemotherapeutic 
agents, one of which was cisplatin.  Evaluations of gene expression profiling using 
RNA from the liver and colon of each strain have been completed.  The gene 
expression study did not include an evaluation of the kidney, histopathology or 
molecular dosimetry endpoints.  The UPLC-HESI-MS/MS method to quantitate CP-
d(GpG) adducts was applied to DNA from tissues of these eight inbred strains of 
mice to gain further understanding of the relationships between adduct accumulation 
and toxicity.   
Previous tissue distribution studies used radiolabeled cisplatin or measured 
total platinum by atomic absorption spectroscopy and have shown the highest 
concentration of cisplatin in the kidney (1,2).  This is not surprising because of the 
nephrotoxicities that have been observed during treatment in the clinic, as well as 
the kidney being the major excretory organ for this compound.  High amounts of 
cisplatin were also observed in the liver, even though no significant liver toxicity was 
reported (1,2).  This may be due to the high concentration of glutathione and other 
thiols in the liver, which may bind cisplatin as a mechanism of detoxification.  Anti-
neoplastic agents such as cisplatin can also cause toxicity in the gastrointestinal 
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tract due to the rapid turnover of cells in this region.  A few studies have reported 
toxicity and/or the formation of cisplatin adducts in the intestine after cisplatin 
treatment (2-4).  Intestinal damage can be tracked through the observation of 
reduction in crypt cell survival as shown in Rebillard et al (4).   Measureable 
concentrations of platinum have also been found in the gastrointestinal tract during 
body distribution studies in rodents and dogs after cisplatin treatment (1, 2). Due to 
the presence of platinum or adducts, coupled with the nephro and gastrointestinal 
related toxicities, we chose to use liver, colon and kidney of the same murine strains 
to determine the molecular dosimetry of intrastrand CP-d(GpG) cross links.  Here we 
evaluate whether the CP-d(GpG) adducts were a suitable biomarker for toxicity, as 
determined by histopathology.  
  
3.2  Materials and Methods 
3.2.1  Study Conditions 
Male inbred mice of eight different strains (FVB/NJ, C3H/HEJ, 129S1/SvImJ, 
A/J, BALB/CJ, C57BL/6J, BTBR T+ TF/J and DBA/2J ; n=3) were injected i.p. with 7 
mg/kg cisplatin by Dr. Haider Ali.  The use of inbred mice in this study allows each 
strain to genetically represent one individual. On days 1 and 3 after injection, the 
mice were euthanized by carbon dioxide anoxia; portions of the kidney, liver, and 
colon were snap-frozen and stored in a –80° C freezer, after removing sections for 
histopathology.  Numerical scale of histology scoring and description was as follows:  
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0= absent or no significant lesions (NSL), 1= minimal lesions (<5%), 2= mild lesions 
(5-25%), 3= moderate lesions (25-50%), 4= marked/severe lesions (>50%). 
We used the FDA’s dose calculator1 to compare the cisplatin dose in our 
mouse study (7 mg/kg) to a low human dose (50 mg/m2) received in the clinic.  
Using an adult mouse weighing 20 g, the total dose at 7 mg/kg cisplatin received 
would be 0.14 mg, which is equal to 21.11 mg/m2 in humans.  Conversely, a dose of 
50 mg/m2 would require 0.33 mg or 16.58 mg/kg in mice. 
 
3.2.2  DNA Isolation from Tissues 
DNA was extracted from frozen kidney (400mg), liver (400mg) or colon tissue 
(150mg) using Gentra PureGene reagents with a modified protocol, as described in 
Chapter 2. Because of reduced amount of colon tissue available for processing, all 
volumes in the procedure were reduced by half when isolating DNA from this tissue.  
The DNA solution was stored at –80° C until CP-d(GpG) adduct analysis. 
 
3.2.3  UPLC-MS/MS Method   
Quantitative LC/MS/MS data were obtained using a Waters Acquity UPLC 
coupled to a Thermo Finnigan TSQ Quantum Ultra triple-quadrupole mass 
spectrometer.  A heated electrospray ionization (HESI) interface was operated in 
positive ionization mode.  The analyzer was operated in single reaction monitoring 
                                                        
1http://www.fda.gov/cder/cancer/animalframe.htm 
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(SRM) mode, monitoring the loss of phosphate, two deoxyriboses and 2 amines 
from CP-d(GpG) (m/z 412.5 to 248, z=2) and [15N5]-CP-d(GpG) IS (m/z 417.5 to 253, 
z=2). Samples were kept at 4° C during analysis, and the sample injection volume 
was 20 µL. An HSS T3 (2.1 mm x 100 mm; 1.8 µm) UPLC column (Waters) was 
conditioned with aqueous 0.1% glacial acetic acid (A3) and methanol (B) at a flow 
rate of 200 µL/min.  Cisplatin adducts were eluted with a linear gradient of 1-10% B 
over 10 min, then to 50% B in 1 min, followed by a 3 min re-equilibration at 1% B.  
The LC flow was diverted to waste for the first 4 min of the gradient.  Instrument 
conditions were optimized for maximum signal of CP-d(GpG) by direct infusion and 
on column injections of analyte standard.  MS settings were as follows: electrospray 
voltage (3000 V), capillary temperature (285 °C), HESI temperature (250 °C), sheath 
and auxiliary gas pressures (35 and 30 arbitrary units), collision energy (25 V), and 
Q2 collision gas pressure (1.5 mTorr).  
 
3.2.4  Quantification 
50 µg of platinated murine DNA from each mouse tissue was spiked with 500 
fmol of Internal Standard.  Next, to separate the adducted nucleotide from the 
surrounding unmodified nucleosides, the samples underwent an enzymatic 
hydrolysis based upon the method previously reported by Eastman (5) as described 
in Chapter 2.  The samples were transferred to MS vials, dried by centrifugal 
lyophilzation and rehydrated in 100 µl 10 mM ammonium acetate in 0.1% glacial 
acetic acid (Buffer A2).  CP-d(GpG) was purified from DNA hydrolysate by HPLC 
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fractionation as described in Chapter 2. Samples were either stored at -20° C or 
immediately rehydrated in 40 µL Buffer A2 for UPLC tandem mass spectrometric 
analysis.   
 
3.3  Results 
3.3.1  Distribution of CP-d(GpG) Adducts in Eight Inbred Mouse Strains 
In two experiments, the trend for distribution of CP-d(GpG) was kidney 
>liver>colon across all strains (Figures 3.1-3.3).  Because the range of overall 
adduct levels in the kidney of the different strains ranged from 5-60 fmol CP-d(GpG) 
per ug DNA in the 1st experiment and 8-27 fmol CP-d(GpG) per ug DNA in the 2nd 
experiment we analyzed the data further to gain a better understanding of the 
apparent variability.  Statistics was performed to identify any significance of CP-
d(GpG) molecular dosimetry by strain, tissue or days after dosing.  An ANOVA for 
each experiment showed a strain and tissue related significance for the first 
experiment (C57BL/6J p=0.0001, DBA/2J p=0.002, kidney p=0.0001, liver p=0.003) 
and a tissue but no strain related significance for the second experiment (kidney 
p=0.0001 and liver p=0.03). 
Due to small numbers of animals and differences between experiments 1 and 
2, limited conclusions can be drawn. In terms of increased or decreased total CP-
d(GpG) adducts by tissue and strain for experiment 2 as compared to experiment 1, 
we see the following trends in Figure 3.3.  For C57BL/6J and DBA/2J, the adduct 
levels were lower in the second experiment for both day 1 and day 3 and for every 
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organ studied.  For FVB/NJ and 129S1/SvImJ, the adduct levels were higher in the 
colon in the second experiment for both day 1 and 3, while other tissues had no 
change.  While for C3H/HEJ, A/J and BALB/CJ mice the results were mixed. 
Next examining the data to determine within an experiment the increase or 
decrease in CP-d(GpG) from day 1 to 3, we observe the following trends.  For 
FVB/NJ mice, the kidney was found to increase in both experiments.  C3H/HEJ 
mice, had a decrease in liver adducts in the first experiment.  A/J mice, had an 
increase in colon adducts in the second experiment.  BALB/CJ mice, experienced a 
decrease in kidney and liver adducts in the first experiment, while the colon adducts 
increased in the second experiment.  C57BL/6J mice had an increase in kidney 
adducts in the second experiment.  Finally, DBA/2J mice had an increase in colon 
adducts in the first experiment.  Otherwise, there were no observed changes in CP-
d(GpG) adducts from day 1 to 3, in either experiment.   
  It is important to note that the colon specimens from FVB/NJ, C3H/HEJ, 
129S1/SvImJ, A/J, and BALB/CJ that were collected with experiment 1 were 
processed together with the tissues from experiment 2.  This knowledge, added to 
the data summarized above as well as the overall colon tissue concentrations of CP-
d(GpG) as shown in Figure 3.3.3 suggests that the variability observed between 
experiments is likely due to either a change in the dosing solution or mouse colony’s 
treatment of a pinworm infestation during the 1st experiment, not in our methodology 
for adduct determination as described in Chapter 2.   
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3.3.2  Histological Observations 
Tables 3.1 and 3.2 contain the cumulative histology scores for all strains in 
each experiment. Figure 3.4 compares histology lesions to concentration of CP-
d(GpG) adducts on day three of both experiments, while Figure 3.5 shows histology 
examples of controls and observed kidney and colon damage caused by cisplatin 
treatment.  The terms and total scores per group used to describe the severity of 
histological lesions in this section are: 0=no significant lesions (NSL), 1-3=minimal 
lesions (<5%), 4-6=mild lesions (5-25%), 7-9=moderate lesions (25-50%), 10-
12=marked lesions (>50%). 
Control animal tissues were only collected for histology during the second 
experiment.  Overall scoring of slides was similar in both experiments, but with 
stronger kidney effects observed in the 2nd experiment.  One exception to this was 
DBA/2J mice which had less overall damage in the 2nd experiment.  However, all 
strains in both experiments showed evidence of nephrotoxicity on day 3.  Another 
difference in histology between the two experiments was the presence of minimal 
liver lesions in the C3H/HEJ mice on day 1 and moderate liver lesions due to 
centrilobular fatty change in the C57BL/6J mice on day three of the first experiment.  
Otherwise the liver had no lesions associated with treatment in either experiment on 
either day.  Because there was minimal toxicity observed in the liver due to 
treatment the following paragraphs will be limited to descriptions of the kidney and 
colon histology.    
In the first experiment (Table 3.1), only three strains showed any significant 
kidney lesions related to treatment 24 hours after dosing. On day one, the 
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129S1/SvImJ, C57BL/6J had minimal lesions due to tubular 
vacuolation/degeneration, BTBR T+ TF/J mice had minimal lesions due to 
apoptosis/necrosis, while DBA/2J mice developed mild kidney lesions due to tubular 
vacuolation/degeneration.  By day three, all strains had developed a minimal to 
moderate level of kidney lesions due to apoptosis/necrosis with some instances of 
tubular vacuolation/degeneration and in each case the severity of lesions had 
increased from the level observed on day 1.  Three strains (A/J, C3H/HEJ, FVB/NJ) 
had minimal apoptotic/necrotic lesions, two (129S1/SvImJ, BALB/CJ) mild 
apoptotic/necrotic lesions and 3 (C57BL/6J, BTBR T+ TF/J, DBA/2J ) moderate 
apoptotic/necrotic lesions with some tubular vacuolation/degeneration.  In 
experiment two (Table 3.2) histologic changes due to treatment were observed for 
the DBA/2J mice at a minimal level on day 1 for the kidney due to tubular 
vacuolation/degeneration, none of the other strains showed any significant kidney 
lesions on day one.  By day three all strains had mild to moderate severity of kidney 
apoptotic/necrotic lesions, with three strains (129S1/SvImJ, A/J, BALB/CJ) showing 
minimal tubular mineralization.  One strain (129S1/SvImJ) had moderate 
apoptotic/necrotic lesions with mild tubular vacuolation/degeneration and minimal 
tubular mineralization, one strain (C57BL/6J) had marked apoptotic/necrotic lesions 
while all other strains had mild apoptotic/necrotic kidney lesions.  Comparing the two 
experiments to one another in terms of kidney lesions, a lower severity was 
observed in experiment two on day 1, however on this day in both experiments 
DBA/2J mice had the greatest damage.  If we then compare the two experiments on 
day three, we see that in experiment one there was less severe kidney damage 
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overall and that only the strain with the greatest severity of kidney lesions 
(C57BL/6J) also has the most severe lesions in experiment two. Control kidneys for 
experiment two showed no significant lesions.   
In the colon on day one of the first experiment, four strains (129S1/SvImJ, 
BALB/CJ, BTBR T+ TF/J, DBA/2J) had minimal apoptotic/necrotic lesions and four 
strains (A/J, C57BL/6J, C3H/HEJ, FVB/NJ) had mild apoptotic/necrotic lesions.  By 
day three, two strains (A/J, FVB/NJ) remained mild; all others had minimal colon 
apoptotic/necrotic lesions.  On day one of the second experiment, one strain 
(C57BL/6J) was mild while all others had minimal apoptotic/necrotic lesions.  By day 
three, two strains (A/J, FVB/NJ) were mild and all others had minimal 
apoptotic/necrotic lesions.  Comparing the severity of these lesions across 
experiments, we see that on day three the A/J and FVB/NJ mice had mild 
apoptotic/necrotic colon lesions in both experiments while all other strains were 
minimally affected.  In experiment one we see two strains (C57BL/6J, C3H/HEJ) 
decrease in severity from day one to three while all others maintain their level of 
severity.  In experiment two we see one strain (C57BL/6J) decrease and two strains 
(A/J, FVB/NJ) increase in severity from day one to three while all others maintain 
their level of severity.  There was an observable increase in lesions on day 1 
compared to controls in the colon of all strains, except FVB/NJ.  A/J, C57BL/6J and 
FVB/NJ appeared to be the most sensitive to colon lesions in both experiments. All 
observed colon lesions were diagnosed as necrosis or apoptosis in the crypt. No 
lesions were apparent in the villi. In control colons, one strain (FVB/NJ) showed 
minimal lesions; all others had no significant lesions.  
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3.4  Discussion 
Histology endpoints of apoptosis/necrosis (all tissues) and tubular 
vacuolation/degeneration (kidney) were important aspects of our study because they 
allowed observation of differences in the toxicity and concentration of platinum 
adducts. While adducts were observed to be highest in the most damaged tissue, no 
overall correlation could be found between increased/decreased histological lesions 
and changes in adduct distribution (Figure 3.4).  Furthermore, there was 
considerable variability between experiments.  Therefore, the data from the two 
experiments could not be combined to increase the sample size. Because colon 
DNA of most strains (excluding C57BL/6J and DBA/2J) from the first experiment 
were processed and quantified with the tissues obtained for the second experiment, 
the observed variability does not appear to be with the UPLC-MS/MS assay.  It is 
possible that the variability comes from some factor associated with the dosing of 
the animals.  Several important issues were identified that need to be considered in 
future studies.   
 This study design contained several confounders that affect the analysis of 
the results. First, because the dose was given by i.p. injection, we cannot be sure of 
the actual dose received by the mice.  One study shows error rates of 11-12% when 
a trained professional performs a one man i.p. injection, due to misplaced injections 
that were most often partly injected into the lumen of the intestine (6).  Second, 
during necropsy we noticed that the mice in the second experiment appeared much 
sicker than those from the first experiment.  Also, one mouse died and several were 
close to death by day three in the 2nd experiment.  The histology slides also show 
  83
more apoptosis/necrosis in the 2nd experiment than the first.  One variable that 
changed from the first experiment to the second was the stock solution of cisplatin 
used for dosing.  The first experiment used cisplatin that had been used previously 
for the dosing of the mice for the gene expression study, while in the second 
experiment a new solution of cisplatin was prepared. Therefore, there may have 
been differences in the preparation of the stock solution for each mouse experiment, 
which could have affected the potency of the cisplatin solutions. Based upon our 
histology data, the newer cisplatin may have been more potent than the cisplatin 
used in dosing the 1st experiment, leading to the observed increased toxicity in the 
2nd experiment which manifested as more apoptosis and necrosis.   
What is poorly understood is the lower molecular dose of the DNA cross links 
in the second experiment. One possible explanation could be the increased cell loss 
due to necrosis, resulting in less adduct being available for quantification in the 
tissues. This explanation would not, however, be the case for liver, as necrosis was 
minor in that tissue. Dosing solution preparation and animal dosing was not 
performed in or by our laboratory.  Therefore, another explanation could be that 
changes in stock solution preparation led to differences in relative amounts of intact 
and aquated cisplatin in the first and second stock solutions, which would affect the 
percent platinum incorporation into cellular DNA and protein.   Jones et al has shown 
aquated cisplatin to be 3 times as nephrotoxic as cisplatin itself in rats (7). In his 
experiments, the aquated form of cisplatin was prepared by placing cisplatin in 
water, which was then allowed to stand at room temperature for two weeks.  Since 
the dosing solution used for the first experiment was what remained from previous 
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dosing of animals for the gene expression study, these conditions could have been 
unknowingly reproduced.  For the second experiment, the previous stock dosing 
solution was gone.  Therefore, new cisplatin was ordered and a new solution made 
immediately before dosing.  This by itself could have caused a greater formation of 
aquated cisplatin, leading to the greater amount of DNA adducts in the first 
experiment. Alternatively, preparation of the cisplatin in a saline and then non-saline 
solution could cause similar differences.    
 One factor unrelated to dosing that may have affected the study was the 
infestation of pinworms in the mouse facility during the first experiment. It is possible 
that the medication given to eradicate the outbreak affected the interaction of 
cisplatin in those mice. In this case, the pinworm treatment may have protected 
against kidney toxicity, while increasing overall adduct formation.  When examining 
this possibility, it is also possible that the pinworm treatment caused the liver toxicity 
observed in the first experiment, as no liver toxicity occurred in the second 
experiment. 
With all of this taken into account, based upon both the histology and CP-
d(GpG) data obtained in these experiments, the C57BL/6J mice appear to be the 
most sensitive and FVB/NJ least sensitive with respect to the adduct burden and 
toxicity in the kidney. It is possible that formation and/or repair of CP-d(GpG) 
adducts could be strain specific.  But due to the lack of correlation of adduct 
formation between our two experiments, we are unable to conclusively make such a 
determination. Furthermore, because of the lack of correlation between 
histopathology and adduct burden, it is possible that the CP-d(GpG) adduct may not 
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be the adduct driving toxicity. Since the highly toxic interstrand cross links have been 
primarily linked to cytotoxicity in dividing cells, it is more likely that the primary 
adducts resulting in kidney toxicity are Pt-protein or Pt-membrane lesions (8).  
However, it is also possible with a more carefully designed study that the CP-d(GpG) 
adduct burden and histology would correlate.  
We could find no consistent difference in adduct concentration for day 1 
versus day 3. In some strains adducts increased, while in others adduct levels 
decreased with time. This is of concern because one would expect a decrease in 
platinum DNA adducts between days one and three due to repair and cell death.  
This study does offer the first reported measurement of CP-d(GpG) adducts in the 
kidney, liver and colon of mice. While our method was able to detect adducts in all 
tissues of all strains, with an n=3 statistical outliers could not be eliminated, therefore 
a larger sample size will be necessary to confirm if observed trends are significant in 
either experiment. For greater statistical power the sample size for a study of this 
type should be at least 6 or optimally 9 mice per group. Additionally because of the 
confounders noted in this report, dosimetry, histology and gene expression studies 
should all be done in a single experiment.  
 Our newly developed method for the quantification of CP-d(GpG) 
adducts was sensitive enough to measure adducts formed using biologically relevant 
doses of cisplatin.  In this study, the dose of cisplatin given is equivalent to ~21 
mg/m2, which is less than half of a typical clinical low dose of cisplatin.  Using the 
molecular dosimetry of these adducts in the kidney we have found the C57BL/6J 
and 129S1/SvImJ strains to be most sensitive and the FVB/NJ strain to be the least 
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sensitive.  However, these designations did not match histopathology scoring. If we 
had been able to use our biomarker to identify sensitive and resistant strains of 
mice, we could have begun looking at the previously obtained gene expression data 
for genes that match the trends observed with the adduct data. Such a correlation 
between adduct burden and gene expression, might have allowed researchers to 
discriminate between species-species differences in DNA damage response and in 
the biodistribution of cisplatin. One confounder to using the previously obtained gene 
expression data is that the kidney was not one of the organs collected for gene 
expression analysis. Because of the nephrotoxic actions of cisplatin, this tissue 
should be included in future combined molecular dosimetry/gene array studies of 
cisplatin. Future genomic studies can be performed to search for haplotypes or gene 
expression patterns that may be associated with cisplatin-sensitive or resistant 
phenotypes.   
A study of this nature has been shown to be of use in understanding 
acetaminophen toxicity.  Heinloth et al. showed gene expression perturbations at 
subtoxic doses of acetaminophen that may have indicated low level cellular injury in 
the liver that was not detected by histopathology or clinical chemistry (9).  When they 
increased the dose of acetaminophen to a toxic level the same genes showed a 
more exaggerated response, leading to the belief that gene expression profiling can 
be used to identify markers of low level cellular injury. Another study used oxidative 
stress biomarkers to provide phenotypic anchors for gene expression profiling of 
acetaminophen-induced oxidative stress (10).  
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In our case, the profiling could be used to detect markers that precede the 
development of resistance to cisplatin treatment.  For the best ultimate translation of 
this and future mouse studies to the clinic, a larger sample size is required to ensure 
proper identification of alleles and a definite phenotypic classification.  Additionally, 
because of the inconsistencies between our experiments we conclude that 
phenotypic markers must be determined using the same animals for both 
biomarkers and gene expression and using larger numbers of animals per group. To 
reduce the size of a study that would follow our suggested model, one could focus 
upon the strains found to be most sensitive (C57BL/6J) and resistant (FVB/NJ) to 
cisplatin kidney toxicity in our experiments.  Because the mode of action for cisplatin 
is not well understood, a complex system of cellular molecular pathways is likely to 
be playing a role in an individual’s response to cisplatin-based chemotherapy.  With 
properly designed pharmacogenomic studies combined with systems biology, 
individualized medicine is on the horizon. However, it is also clear that a high degree 
of consistency must be required in the dosing and evaluation of endpoints.   
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Figure 3.5  Kidney histology slide pictures. 
The top panel contains an example of control kidney shown at multiple 
magnifications.  The bottom panel contains representative slides showing 
each level of damage observed in our study.   1=minimal lesions; 2=mild 
lesions; 3=moderate lesions; 4= marked lesions 
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. 
Figure 3.6  Colon histology slide pictures 
The top panel shows an example of control colon at multiple magnifications. 
The bottom panel contains representative slides showing each level of 
damage observed in our study.   1=minimal lesions; 2=mild lesions  
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TABLES 
 
Tissue Time 
in 
days 
129S1/ 
SvImJ 
A/J BALB/ 
cJ 
C57BL/ 
6J 
BTBR 
T+ 
TF/J 
C3H/ 
HEJ 
DBA/ 
2J  
FVB/ 
NJ 
1  0,1c 0 0 0,2a,3c 1 0 0,6c 0 
K
id
ne
y 
3 5 3 5 9,2c,4d 9 3 3,8c 1,2c 
1 0 1* 0 0, 2a 2* 1 0 0 
Li
ve
r 
3 0 0 0 0, 8b 6* 0 2* 2* 
1 3 4 2 6 3 4 3 4 
Se
pt
em
be
r H
is
to
lo
gy
 S
co
re
s 
C
ol
on
 
3 3 5 3 3 3 3 3 4 
n=3; *= time of death or unrelated to treatment; a= lymphocytes/plasma cells chronic lesion not 
related to treatment; b=centrilobular fatty change; c= tubular vacuolation/degeneration; d= tubular 
mineralization 
 
Table 3.1  Histopathology scoring of September (1st) cisplatin mouse experiment. 
Scores are reported here as the composite of three animals individual histology 
scores.  Description of numerical score is as follows: 0= absent of no significant 
lesions, 1-3=minimal lesions (<5%), 4-6=mild lesions (5-25%), 7-9=moderate lesions 
(25-50%), 10-12=marked/severe lesions (>50%).  In the above table, the first 
number refers to necrosis/apoptosis in tissue and following number(s) indicate other 
damage as indicated by superscript letters.  
 
 
  101
 
Tissue Time 
in 
days 
129S1/ 
SvImJ 
A/J BALB/ 
cJ 
C57BL/ 
6J 
BTBR  
T+ TF/J 
C3H/ 
HEJ 
DBA/ 
2J  
FVB
/ NJ 
0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0,1c 0 
K
id
ne
y 
3 9,5c,3
d 
6,2
d 
6,1d 12 N
ot
   
A
va
ila
bl
e 
6 5 5 
0 0 0 0 0 0 0 1 
1 0 0 0 1* 0 2* 0 
Li
ve
r 
3 0 0 0 0 
N
ot
  
A
va
ila
bl
e 
0 2* 1* 
0 0 0 0 0 0 0 1 
1 2 1 3 4± 3 3 3 
D
ec
em
be
r H
is
to
lo
gy
 S
co
re
s 
C
ol
on
 
3 3 5 3 2# 
N
ot
 
A
va
ila
bl
e 
3 3± 6 
n=3; *= time of death or unrelated to treatment; a= lymphocytes/plasma cells chronic lesion not 
related to treatment; b=centrilobular fatty change; c= tubular vacuolation/degeneration; d= tubular 
mineralization; ± = only one section of colon on histology slide for one animal;  # = autolysis of one 
animal’s tissue 
 
Table 3.2  Histopathology scoring of December (2nd) cisplatin mouse experiment. 
Scores are reported here as the composite of three animals’ individual histology 
scores.  Time in days of 0 is for control animals.  Description of numerical score is as 
follows: 0= absent of no significant lesions, 1-3=minimal lesions (<5%), 4-6=mild 
lesions (5-25%), 7-9=moderate lesions (25-50%), 10-12=marked/severe lesions 
(>50%).  In the above table, the first number refers to necrosis/apoptosis in tissue 
and following number(s) indicate other damage as indicated by superscript letters.  
  102
REFERENCES 
 
1. Page RL, Lee J, Riviere JE, Dodge RK, Thrall DE, Dewhirst MW.  Absence of 
whole body hyperthermia effect on cisplatin distribution in spontaneous 
canine tumors. Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1097-102. 
2. Bénard P, Desplanches G, Macquet JP, Simon J.  Whole-body 
autoradiographic study of the distribution of 195mPt in healthy and tumor-
bearing mice treated with labeled cisplatin. Cancer Treat Rep. 1983 
May;67(5):457-66. 
3. Newman RA, Khokhar AR, Sunderland BA, Travis EL, Bulger RE.  A 
comparison in rodents of renal and intestinal toxicity of cisplatin and a new  
water-soluble antitumor platinum complex: N-methyl-iminodiacetato-
diaminocyclohexane platinum (II). Toxicol Appl Pharmacol. 1986 
Jul;84(3):454-63. 
4. Rebillard A, Rioux-Leclercq N, Muller C, Bellaud P, Jouan F, Meurette O, 
Jouan E, Vernhet L, Le Quément C, Carpinteiro A, Schenck M, Lagadic-
Gossmann D, Gulbins E, Dimanche-Boitrel MT.  Acid sphingomyelinase 
deficiency protects from cisplatin-induced gastrointestinal damage.  
Oncogene. 2008 Nov 20;27(51):6590-5. 
5. Eastman, A.  (1986) Reevaluation of interaction of cis-
dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 25, 3912-3915. 
6. Arioli V, Rossi E.  Errors related to different techniques of intraperitoneal 
injection in mice.  Appl Microbiol. 1970 Apr;19(4):704-5. 
7. Jones MM, Basinger MA, Beaty JA, Holscher MA. The relative nephrotoxicity 
of cisplatin, cis-[Pt(NH3)2(guanosine)2]2+, and the hydrolysis product of 
cisplatin in the rat. Cancer Chemother Pharmacol. 1991; 29: 29-32. 
8. Plooy AC, van Dijk M, Lohman PH.  Induction and repair of DNA cross links in 
chinese hamster ovary cells treated with various platinum coordination 
compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, 
and antitumor activity.  Cancer Res. 1984 May;44(5):2043-51. 
9. Heinloth AN, Boorman GA, Foley JF, Flagler ND, Paules RS. Gene 
expression analysis offers unique advantages to histopathology in liver biopsy 
evaluations. Toxicol Pathol. 2007;35(2):276-83. 
10. Powell CL, Kosyk O, Ross PK, Schoonhoven R, Boysen G, Swenberg JA, 
Heinloth AN, Boorman GA, Cunningham ML, Paules RS, Rusyn I.  
Phenotypic anchoring of acetaminophen-induced oxidative stress with gene 
expression profiles in rat liver. Toxicol Sci. 2006 Sep;93(1):213-22.  
CHAPTER 4 
CONCLUSIONS AND FUTURE DIRECTIONS 
We have developed a sensitive and specific method to quantify cisplatin 1,2 
guanine-guanine intrastrand cross links by tandem mass spectrometry.  The 
sensitivity of this method is comparable to the 32P postlabeling method, which was 
the most sensitive method for the quantification of individual cisplatin derived 
adducts. None of the previously published methods included an internal standard. 
The use of an internal standard is necessary to correct for error that can be caused 
during sample preparation or due to differences in equipment sensitivity between 
runs.  Our method has the benefit of an internal standard, provides structural 
confirmation of adducts, and does not require the use of radioactivity.  Both cisplatin 
and carboplatin form chemically identical platinum adducts, therefore this assay can 
be used to detect the Pt-d(GpG) adduct for both agents.  Important advances and 
conclusions gained during the development of our method are summarized in the 
following list. 
1. Our method is the first to use a stable isotope-labeled internal standard 
during mass spectrometric quantification of cisplatin-DNA adducts. 
2. Our method has a limit of quantification (LOQ) of 0.12 fmol CP-d(GpG) per 
µg DNA or 3.7 adducts per 108 nucleotides, requiring only 25 µg of DNA on 
column. 
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3. We have shown that we are able to measure adducts formed in vitro and in 
vivo at biologically relevant doses of cisplatin.   
As discussed in Chapter 2, studies using peripheral blood cells of humans 
treated with cisplatin detected up to 0.25 fmol cisplatin intrastrand adducts per µg 
DNA in patients with testicular cancer and 0.16-14.1 fmol CP-d(GpG) per µg DNA in 
patients with gastric cancer (1,2). CP-d(GpG) adduct levels have been reported 
using 32P postlabeling to be 4-5 times higher in primary head and neck squamous 
cell carcinoma (HNSCC) tumors than in peripheral blood cells or buccal cells 
obtained after intravenous or intraarterial administration of 100-150 mg/m2 cisplatin 
(3). Therefore, our limit of quantification should be sufficient to measure cisplatin 
guanine-guanine adducts as a surrogate marker of dose using peripheral blood cells 
or directly in biopsied samples in a clinical setting. This highly sensitive and specific 
method could then be utilized in clinical studies to monitor adduct levels to provide a 
better understanding of cisplatin detoxification prior to Pt-DNA adduct formation and 
cisplatin-DNA adduct repair.  Clinical samples that could be measured by this 
method include lymphocytes, buccal cells, and other tissues obtained during biopsy 
from patients which have received either cisplatin or carboplatin therapy.  
Furthermore, with some modifications this method could be used also to quantify the 
Pt-d(ApG) adduct, allowing the detection of ~95% of all formed platinum adducts.  
In our mouse study using ~21 mg/m2 cisplatin, we were able to measure 
adducts one and three days after dosing.  A normal clinical dose of cisplatin is 50-
100 mg/m2, which suggests that we would be able to detect adducts several days 
after treatment in tissues of patients treated with cisplatin or carboplatin therapy. 
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Using our newly developed UPLC-MS/MS method, we determined the molecular 
dosimetry of cisplatin intrastrand guanine-guanine adducts after 24 and 72 hours in 
the kidney, liver and colon.  The literature shows that platinum levels are the highest 
in the tumor, kidney, and liver following treatment. Since these studies measured 
total platinum, we were interested in measuring the CP-d(GpG) to see whether the 
kidney or the liver was the most affected site.   
As we show in chapter 3, the molecular dosimetry data obtained were 
analyzed to determine if there was a strain, tissue or time point at which there was a 
significant increase or decrease in CP-d(GpG) adduct concentration. Using these 
characteristics, our initial plans were to identify cisplatin sensitive and resistant 
phenotypes which would ultimately be used to search the microarray data for 
affected genes.  The correlation of the aforementioned cisplatin dosimetry with gene 
expression data could provide insight about genes or polymorphisms in the human 
population that may cause a cancer patient to be sensitive or resistant to cisplatin 
treatment.  In the following paragraphs, we will use our experiences from this 
research to suggest ways to appropriately design and implement combined 
dosimetry and gene expression studies, which will provide better data to allow these 
correlations.  This knowledge one day could allow patients undergo genetic testing 
prior to treatment that would determine the optimal therapies for that individual.   
Because our first molecular dosimetry study had a small sample size (n=3) 
another study of the same size was performed to strengthen our data.  However, 
there was considerable variability between the two molecular dosimetry studies.  
Therefore, the data from the studies could not be combined to increase our sampling 
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size. Because of confounding factors such as, mice in the 1st study undergoing 
treatment for a pinworm infestation and fresh cisplatin used for the 2nd but not the 1st 
study, it is difficult to make direct comparisons of Pt-DNA adduct levels and histology 
data between the studies. The range of overall adduct levels in the kidney, the most 
affected tissue, of the different strains was 5-60 fmol CP-d(GpG) per µg DNA in the 
1st study and 8-27 fmol CP-d(GpG) per µg DNA in the 2nd study. Furthermore, the 
levels of organ toxicity observed through histopathology analysis were different 
within strains between studies.  These factors taken together invalidate the use of 
the current dosimetry data set for correlation with the microarray data, in which 
pooled RNA was obtained from a different set of animals.  
Another study with a larger number of animals of similar age and weight, and 
the use of verified dosing solutions would provide a more consistent and reliable 
data set for analysis. Likewise, the optimal design for a study involving both 
microarray and molecular dosimetry data collection would include the use of the 
same set of animals; this would ensure that increases or decreased observed in the 
array data would be directly comparable to cisplatin adduct molecular dosimetry.  
Also, since it is common practice for those employing microarray techniques to pool 
RNA to ensure an appropriate amount for analysis, for this type of study DNA from 
the same animals should also be pooled to ensure data will later be directly 
comparable. It should be noted that we have shown that the UPLC-MS/MS method 
has enough sensitivity to quantitate adducts from individual mice in tissues such as 
the colon from which a limited amount (<100 µg) of DNA can be isolated.  The time 
points in the microarray study of 1, 3 and 7 days after dosing were selected based 
 107
on a colon cancer model and the time it takes cells to go from “the crypt to the tip”.  
By the 7th day of treatment, the colon crypt cells would have been shed from the villi 
and the repair of CP-d(GpG) adducts in the kidney and liver was expected to be 
complete.  Also, preliminary data from the microarray study were available which 
suggested tissues would be destroyed or the animals would be dead from treatment 
by the 7th day.  Therefore, the studies we performed only collected data at the 1 and 
3 day time points.  However, in a study that combines these techniques measuring 
adducts on the 7th day should be considered.  This would allow to the study to follow 
intended the “tip to crypt” study design and determine adduct levels on day 7, 
providing a more complete analysis using the corresponding gene expression data.   
Because of the necessity of pooling three animals per sample for the 
microarray portion of the study and to use enough animals for optimal statistical 
analysis, an n=9 x 3 (21) would be required for each time point (controls, 1, 3, 7 day) 
and each strain (8) for a total of 672 animals.  Even more animals may be required 
so that sufficient RNA and DNA can be isolated from the same tissues for analysis 
by both methods, making this a very large and expensive study.  Alternatively, one 
could narrow the study to only include those strains most likely sensitive (BL6) and 
resistant (FVB) to cisplatin treatment, as determined during our molecular dosimetry 
studies.  
Next, to more accurately mimic the manner in which patients are treated with 
cisplatin, a mini-pump allowing infusion of cisplatin over a longer time period and 
hydration pre- and post- dosing would be preferable to bolus i.p. injections. Using 
this mini-pump infusion of cisplatin with adequate hydration, it would be interesting to 
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see if there is a shift from the kidney having the highest concentration of CP-d(GpG) 
adducts. In our study design, the liver may develop an increased concentration of 
CP-d(GpG) adducts, if the kidney toxicity was reduced in this manner. Also, using 
that method of drug delivery combined with hydration, one would not expect the 
mice to be as sick (or in some cases dead) on day 3, since these outcomes were 
believed to be due to kidney failure.  Conclusions from our animal study are 
summarized in the following list. 
1. In both animal studies, the trend for distribution of CP-d(GpG) across all 
strain tissues was kidney>liver>colon. 
2. While adducts were observed to be highest in the kidney, no overall 
correlation could be found between increased/decreased lesions in tissues 
and factors such as time after dosing or mouse strain. This may be due to the 
variability between our two studies.  
3. Therefore, another study with a larger number of animals is needed to 
identify a sensitive or resistant phenotype using molecular dosimetry and 
microarray data obtained from the same set of animals. 
 
As discussed in the introduction, several studies have compared platinum 
based DNA adducts obtained from normal vs. tumor tissue.  These studies are not 
consistent in whether or not there is a correlation between adduct levels in normal 
tissues and survival or response to treatment.  However, in each of these studies the 
“normal” tissues utilized are lymphocytes or buccal cells and the tumor tissue is 
obtained from biopsied tissue.  This is generally done because there are limitations 
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to the human tissues one can obtain for research.  However, it would be of interest 
to see if there is a correlation between normal and tumor adduct concentrations 
when the same tissue type is used.  Such studies could be performed in animals.  
However as we learned during our animal study, great care must be taken when 
designing an animal study to ensure that the data obtained is consistent and of use 
when performing data analysis. 
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